Form 8-K

8-K — Edesa Biotech, Inc.

Accession: 0001171843-26-005686

Filed: 2026-08-20

Period: 2026-08-19

CIK: 0001540159

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — f8k_081726.htm (Primary)

EX-1.1 — EXHIBIT 1.1 (exh_11.htm)

EX-4.1 — EXHIBIT 4.1 (exh_41.htm)

EX-4.2 — EXHIBIT 4.2 (exh_42.htm)

EX-5.1 — EXHIBIT 5.1 (exh_51.htm)

EX-5.2 — EXHIBIT 5.2 (exh_52.htm)

EX-99.1 — EXHIBIT 99.1 (exh_991.htm)

EX-99.2 — EXHIBIT 99.2 (exh_992.htm)

GRAPHIC (fasken.jpg)

GRAPHIC (exh51hdr.jpg)

GRAPHIC (lslogo.jpg)

GRAPHIC (lsfoot.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: f8k_081726.htm · Sequence: 1

false

0001540159

2026-08-19

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 19, 2026

Edesa Biotech, Inc.

(Exact Name of Registrant as Specified in its Charter)

British Columbia, Canada

001-37619

N/A

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

100 Spy Court, Markham, Ontario, Canada

L3R 5H6

(Address of Principal Executive Offices)

(Zip Code)

(289) 800-9600

Registrant’s telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy

the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act

(17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17

CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the

Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the

Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of exchange on which registered

Common Shares

EDSA

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule

405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2

of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use

the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a)

of the Exchange Act. ☐

Item 1.01 Entry into a Material Definitive Agreement.

On August 19, 2026, Edesa Biotech, Inc. (the “Company”) entered into an underwriting

agreement (the “Underwriting Agreement”) with Guggenheim Securities, LLC (“Guggenheim Securities”), as representative

of the several underwriters listed in Schedule 1 thereto (the “Underwriters”), in connection with the issuance and sale, in

an underwritten, registered offering (the “Offering”), of: (i) 3,870,500 shares (the “Offering Shares”) of the

Company’s common shares, without par value (the “Common Shares”) with accompanying common share warrants (the “Common

Share Warrants”) to purchase up to 3,870,500 Common Shares, at a combined offering price of $5.50 per share and accompanying Common

Share Warrant; and (ii) pre-funded warrants (the “Pre-Funded Warrants” and together with the Common Share Warrants, the “Warrants”)

to purchase up to an aggregate of 675,000 Common Shares with accompanying Common Share Warrants to purchase up to 675,000 Common Shares,

at a combined offering price of $5.4999 per Pre-Funded Warrant and accompanying Common Share Warrant, which represents the combined offering

price per Share (as defined below) and accompanying Common Share Warrant less the $0.0001 per share exercise price for each such Pre-Funded

Warrant. In addition, pursuant to the Underwriting Agreement, the Company granted the Underwriters a 30-day option to purchase up to 681,825

additional Common Shares (the “Option Shares” and together with the Offering Shares, the “Shares”) and accompanying

Common Share Warrants to purchase up to 681,825 Common Shares on the same terms as the Offering Shares and accompanying Common Share Warrants.

The Company expects to receive net proceeds of approximately $23.1 million from the

Offering, after deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. The

Offering is expected to close on or about August 21, 2026, subject to customary closing conditions. The Company intends to use the

net proceeds from the Offering for general corporate purposes, which may include working capital, capital expenditures and research

and development and manufacturing expenses. The Underwriting Agreement contains customary representations, warranties and covenants

of the Company, conditions to closing, indemnification obligations of the Company and the Underwriters, including for liabilities

under the Securities Act of 1933, as amended (the “Securities Act”), other obligations of the parties and

termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for

purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be

subject to limitations agreed upon by the contracting parties. Pursuant to the terms of the Underwriting Agreement, the Company has

agreed to certain restrictions on the issuance and sale of its Common Shares and securities convertible into Common Shares during

the 90-day period following the date of the Prospectus Supplement.

Subject to certain exceptions, the Company’s executive officers and directors agreed not

to sell or otherwise dispose of any Common Shares held by them for a period beginning on the date of execution of the applicable lock-up

agreements by each such executive officer and director and ending 90 days after the date of the Prospectus Supplement (as defined herein)

filed with the U.S. Securities and Exchange Commission (the “SEC”) in connection with the Offering pursuant to Rule 424(b)

of the Securities Act, without first obtaining the written consent of Guggenheim Securities.

The Common Share Warrants will each be exercisable for one Common Share at an exercise price

of $7.50 per share. The Common Share Warrants will be exercisable at any time after their original issuance and may be exercised until

the date that is the earlier of (i) the 18-month anniversary of the original issuance date and (ii) the 30th day following

the date of the Company’s public announcement of Phase 2 vitiligo topline data for EB06. A holder of the Common Share Warrants may

not exercise any portion of the Common Share Warrants to the extent that such holder would beneficially own more than 4.99% (or 9.99%,

at the election of each holder prior to issuance) of the number of Common Shares outstanding immediately after giving effect to such exercise,

as such percentage ownership is determined in accordance with the terms of the Common Share Warrants. However, upon at least 61 days’

prior notice from a holder to the Company, such holder may increase or decrease such beneficial ownership limitation, as applicable, up

to 9.99% of the Common Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined

in accordance with the terms of the Common Share Warrants. The exercise price and the number of Common Shares issuable upon exercise of

the Common Share Warrants are subject to appropriate adjustment in the event of certain share dividends, share splits, share combinations

or other similar reclassifications affecting the Common Shares.

The Pre-Funded Warrants will have an initial exercise price of $0.0001 per share and will be

immediately exercisable upon issuance. The Pre-Funded Warrants do not have a termination date. A holder of the Pre-Funded Warrants may

not exercise any portion of the Pre-Funded Warrants to the extent that such holder would beneficially own more than 4.99% (or 9.99%, at

the election of each holder prior to issuance) of the number of Common Shares outstanding immediately after giving effect to such exercise,

as such percentage ownership is determined in accordance with the terms of the Pre-Funded Warrants. However, upon at least 61 days’

prior notice from a holder to the Company, such holder may increase or decrease such beneficial ownership limitation, as applicable, up

to 9.99% of the Common Shares outstanding immediately after giving effect to the exercise, as such percentage ownership is determined

in accordance with the terms of the Pre-Funded Warrants. The exercise price and the number of Common Shares issuable upon exercise of

the Pre-Funded Warrants are subject to appropriate adjustment in the event of certain share dividends, share splits, share combinations

or other similar reclassifications affecting the Common Shares.

The Offering is being made pursuant to (1) an effective Registration Statement on Form S-3 (File

No. 333-288966), declared effective by the SEC on September 9, 2025, and (2) a related prospectus supplement dated August 19, 2026 (the

“Prospectus Supplement”).

The foregoing summaries of the Offering, the Underwriting Agreement, the Common Share Warrants,

the Pre-Funded Warrants and the Shares do not purport to be complete and are qualified in their entirety by reference to the definitive

transaction documents. Copies of the Underwriting Agreement, the form of Common Share Warrant and the form of Pre-Funded Warrant are attached

hereto as Exhibits 1.1, 4.1 and 4.2, respectively, and are incorporated herein by reference.

A copy of the Fasken Martineau DuMoulin LLP opinion relating to the legality of the issuance

and sale of the Shares offered in the Offering and the Common Shares issuable upon exercise of the Warrants in the Offering is attached

as Exhibit 5.1. A copy of the Lowenstein Sandler LLP opinion relating to the legality of the issuance and sale of the Warrants in the

Offering is attached as Exhibit 5.2.

Item 8.01 Other Events.

On August 19, 2026, the Company issued a press release announcing the launch of the Offering.

A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

On August 19, 2026, the Company issued a press release announcing the pricing of the Offering.

A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements that involve estimates,

assumptions, risks and uncertainties. Forward-looking statements include, but are not limited to, statements related to the amount of

proceeds expected from the Offering, the intended use of proceeds from the Offering and the timing and certainty of completion of the

Offering. The risks and uncertainties relating to the Company and the Offering include general market conditions, the proposed restructuring

of the Company’s outstanding indebtedness, the Company’s ability to complete the Offering on favorable terms, or at all, as

well as other risks detailed from time to time in the Company’s filings with the SEC, including in its Annual Report on Form 10-K

for the year ended September 30, 2025 and the Prospectus Supplement. These documents contain important factors that could cause actual

results to differ from current expectations and from the forward-looking statements contained in this Current Report on Form 8-K. These

forward-looking statements speak only as of the date of this Current Report on Form 8-K and the Company undertakes no obligation to publicly

update any forward-looking statements to reflect new information, events or circumstances after the date of this Current Report on Form

8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

1.1

Underwriting Agreement, dated August 19, 2026, by and between the Company

and Guggenheim Securities, LLC.

4.1

Form of Common Share Warrant.

4.2

Form of Pre-Funded Warrant.

5.1

Opinion of Fasken Martineau DuMoulin LLP.

5.2

Opinion of Lowenstein Sandler LLP.

23.1

Consent of Fasken Martineau DuMoulin LLP (included in Exhibit 5.1).

23.2

Consent of Lowenstein Sandler LLP (included in Exhibit 5.2).

99.1

Press release dated August 19, 2026.

99.2

Press release dated August 19, 2026.

104

Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the

registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Edesa Biotech, Inc.

Date: August 20, 2026

By:

/s/ Peter J. Weiler

Name:

Peter J. Weiler

Title:

Chief Financial Officer

EX-1.1 — EXHIBIT 1.1

EX-1.1

Filename: exh_11.htm · Sequence: 2

Exhibit 1.1

Execution Version

EDESA BIOTECH, INC.

3,870,500 Common Shares,

Pre-Funded Warrants to Purchase up to 675,000 Common Shares,

and

Warrants to Purchase up to 4,545,500 Common Shares

Underwriting Agreement

August 19, 2026

Guggenheim Securities, LLC,

as Representative of the several Underwriters named

in Schedule 1 hereto

c/o Guggenheim Securities, LLC

330 Madison Avenue

New York, NY 10017

Ladies and Gentlemen:

Edesa Biotech, Inc., a company organized under the

laws of British Columbia, Canada (the “Company”), proposes to issue and sell to the several underwriters named in Schedule

1 (the “Underwriters”) an aggregate of (i) 3,870,500 common shares, without par value (“Common Shares”),

of the Company (the “Underwritten Shares”), (ii) pre-funded warrants to purchase up to 675,000 Common Shares in the

form set forth in Exhibit A hereto (the “Pre-Funded Warrants”), (iii) warrants to purchase up to 4,545,500 Common

Shares (the “Underwritten Common Warrants”), and (iv) at the option of the Underwriters, up to 681,825 additional Common

Shares (the “Option Shares” and, collectively with the Underwritten Shares, the “Shares”) with accompanying

warrants to purchase up to 681,825 Common Shares (the “Option Common Warrants” and, together with the Underwritten

Common Warrants, the “Common Warrants” and, together with the Pre-Funded Warrants, the “Warrants”).

Each Share or Pre-Funded Warrant is being sold together with one Common Warrant to purchase one Common Share at an exercise price of $7.50

per Common Share. The Shares and the Warrants are collectively referred to herein as the “Securities.” The Common Shares

underlying the Warrants are herein referred to as the “Warrant Shares.” Guggenheim Securities, LLC (“Guggenheim

Securities”) has agreed to act as representative of the several Underwriters (in such capacity, the “Representative”)

in connection with the public offering and sale of the Securities. To the extent there are no additional underwriters listed on Schedule

1, the term “Representative” as used herein shall mean you, as Underwriter, and the term “Underwriters” shall

mean either the singular or the plural, as the context requires.

The Company hereby confirms its agreement with the

several Underwriters concerning the purchase and sale of the Securities, as follows:

Registration Statement. The Company has prepared and filed with the Securities and Exchange Commission (the “Commission”)

under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Securities

Act”), a registration statement on Form S-3 (File No. 333-288966), including a prospectus (the “Base Prospectus”),

relating to the Securities, which shelf registration statement has been declared effective by the Commission. Such registration statement,

as amended at the time it became effective, including the exhibits and any schedules thereto at such time, the documents incorporated

or deemed to be incorporated by reference therein at such time pursuant to Item 12 of Form S-3 under the Securities Act and the documents

otherwise deemed to be a part thereof as of such time pursuant to Rule 430B under the Securities Act (“Rule 430B”),

is referred to herein as the “Registration Statement;” provided, however, that the “Registration

Statement” without reference to a time means such registration statement as amended by any post-effective amendments thereto as

of the time of the first contract of sale for the Securities, which time shall be considered the “new effective date” of such

registration statement with respect to the Securities within the meaning of paragraph (f)(2) of Rule 430B, including the exhibits and

schedules thereto as of such time, the documents incorporated or deemed to be incorporated by reference therein at such time pursuant

to Item 12 of Form S-3 under the Securities Act and the documents otherwise deemed to be a part thereof as of such time pursuant to Rule

430B.

Any registration statement filed pursuant to Rule 462(b)

of the Securities Act is herein called the “Rule 462(b) Registration Statement” and, after such filing, the term “Registration

Statement” shall include the Rule 462(b) Registration Statement. Each preliminary prospectus supplement used in connection with

the public offering of the Securities, if any, including the Base Prospectus and the documents incorporated or deemed to be incorporated

by reference therein pursuant to Item 12 of Form S-3 under the Securities Act, are collectively referred to herein as a “preliminary

prospectus.” Promptly after execution and delivery of this Agreement, the Company will prepare and file a final prospectus supplement

relating to the Securities in accordance with the provisions of Rule 424(b) of the Securities Act (“Rule 424(b)”).

The final prospectus supplement, in the form first furnished or made available to the Underwriters for use in connection with the public

offering of the Securities, including the Base Prospectus and the documents incorporated or deemed to be incorporated by reference therein

pursuant to Item 12 of Form S-3 under the Securities Act, are collectively referred to herein as the “Prospectus.”

For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment

or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering,

Analysis and Retrieval system (or any successor system) (“EDGAR”). Capitalized terms used but not defined herein shall

have the meanings given to such terms in the Registration Statement and the Prospectus.

“Applicable Time” means 8:00 P.M.,

New York City time, on August 19, 2026.

“Pricing Disclosure Package” means

the preliminary prospectus, as amended or supplemented immediately prior to the Applicable Time, together with the information included

in Annex A(b) hereto and each Issuer Free Writing Prospectus (as defined below) issued at or prior to the Applicable Time, each “free-writing

prospectus” (as defined pursuant to Rule 405 under the Securities Act) issued at or prior to the Applicable Time and listed on Annex

A(a) hereto and the Base Prospectus, all considered together.

All references in this Agreement to financial statements

and schedules and other information which is “contained,” “included” or “stated” (or other references

of like import) in the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include all such financial

statements and schedules and other information incorporated or deemed incorporated by reference in the Registration Statement, any preliminary

prospectus or the Prospectus, as the case may be, prior to the execution and delivery of this Agreement; and all references in this Agreement

to amendments or supplements to the Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to include the

filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively,

the “Exchange Act”), incorporated or deemed to be incorporated by reference in the Registration Statement, such preliminary

prospectus or the Prospectus, as the case may be, at or after the execution and delivery of this Agreement.

Purchase of the Securities by the Underwriters.

(a)

The Company agrees to issue and sell the Underwritten Shares, the Pre-Funded Warrants and the Underwritten Common Warrants to the

several Underwriters as provided in this underwriting agreement (this “Agreement”). On the basis of the representations,

warranties and agreements set forth herein and subject to the conditions set forth herein, the Underwriters agree, severally and not jointly,

to purchase at a combined purchase price for each (i) Underwritten Share and accompanying Underwritten Common Warrant of $5.17 (the “Per

Share Purchase Price”) and (ii) Pre-Funded Warrant and accompanying Underwritten Common Warrant of $5.1699 (the “Per

Pre-Funded Warrant Purchase Price”), from the Company the respective number of Securities set forth opposite their names in

Schedule 1 hereto.

In addition, the Company agrees to issue and sell the

Option Shares and accompanying Option Common Warrants to the several Underwriters as provided in this Agreement, and the Underwriters,

severally and not jointly, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions

set forth herein, shall have the option to purchase from the Company the Option Shares and accompanying Option Common Warrants at the

Per Share Purchase Price, less an amount per share equal to any dividends or distributions declared by the Company and payable on the

Underwritten Shares and the Underwritten Common Warrants but not payable on the Option Shares and the accompanying Option Common Warrants.

The option to purchase Option Shares and accompanying

Option Common Warrants may be exercised at any time in whole, or from time to time in part, on or before the 30th day following the date

of the Prospectus, by written notice from the Representative to the Company. Such notice shall set forth the aggregate number of Option

Shares and accompanying Option Common Warrants as to which the option is being exercised and the date and time when the Option Shares

and accompanying Option Common Warrants are to be delivered and paid for, which may be the same date and time as the Closing Date (as

hereinafter defined) but shall not be earlier than the Closing Date nor later than the 10th full business day (as hereinafter defined)

after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section 11 hereof). Any such

notice shall be given at least two business days prior to the date and time of delivery specified therein. If any Option Shares and accompanying

Option Common Warrants are to be purchased, each Underwriter agrees, severally and not jointly, to purchase the number of Option Shares

and accompanying Option Common Warrants (subject to such adjustments to eliminate fractional shares or warrants as the Representative

may determine) that bears the same proportion to the total number of Option Shares and accompanying Option Common Warrants to be purchased

as the number of Underwritten Shares and accompanying Underwritten Common Warrants set forth in Schedule 1 opposite the name of

such Underwriter bears to the total number of Underwritten Shares and accompanying Underwritten Common Warrants.

(b)

The Company understands that the Underwriters intend to make a public offering of the Securities, and initially to offer the Securities

on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell

Securities to or through any of their respective affiliates.

Payment for the Securities shall be made by wire transfer

in immediately available funds to the account specified by the Company to the Representative and, in the case of the Underwritten Shares,

Pre-Funded Warrants and the Underwritten Common Warrants, at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel

for the Underwriters at 10:00 A.M., New York City time, on August 21, 2026, or at such other time or place on the same or such other date,

not later than the fifth business day thereafter, as the Representative and the Company may agree upon in writing or, in the case of the

Option Shares and accompanying Option Common Warrants, on the date and at the time and place specified by the Representative in the written

notice of its election to purchase such Option Shares and accompanying Option Common Warrants. The time and date of such payment for the

Securities is referred to herein as the “Closing Date,” and the time and date for such payment for the Option Shares

and accompanying Option Common Warrants, if other than the Closing Date, is herein referred to as the “Additional Closing Date.”

Notwithstanding the foregoing, the Company and the

Representative shall instruct purchasers of the Pre-Funded Warrants and accompanying Underwritten Common Warrants in the offering to make

payment for the Pre-Funded Warrants and accompanying Underwritten Common Warrants on the Closing Date to the Company by wire transfer

in immediately available funds to the account specified by the Company at the “Combined Public Offering Price per Pre-Funded Warrant

and Accompanying Underwritten Common Warrant” set forth in Annex A(b) hereto, in lieu of payment by the Underwriters for such Pre-Funded

Warrants and accompanying Underwritten Common Warrants, and the Company shall deliver such Pre-Funded Warrants and accompanying Underwritten

Common Warrants to such purchasers on the Closing Date in definitive form against such payment, in lieu of the Company’s obligation

to deliver such Pre-Funded Warrants and accompanying Underwritten Common Warrants to the Underwriters; provided that, the Representative

shall withhold $0.33 per Pre-Funded Warrant and accompanying Underwritten Common Warrant with respect to such Pre-Funded Warrants and

accompanying Underwritten Common Warrants as an offset against the payment owed by the Underwriters to the Company with respect to the

Securities hereunder.

In the event that any purchaser of the Pre-Funded Warrants

and accompanying Underwritten Common Warrants in the offering fails to make payment to the Company for all or part of the Pre-Funded Warrants

and accompanying Underwritten Common Warrants (the “Failed Warrants”) on the Closing Date, as the case may be, the

Underwriters may elect, by written notice to the Company and payment of the purchase price by wire transfer in immediately available funds

to the account specified by the Company at the location and time designated in this Section 2(b) for the Closing Date or the

Additional Closing Date, as the case may be, to receive Common Shares and accompanying Common Warrants at the applicable purchase price

in lieu of the Failed Warrants that were otherwise to have been delivered to the purchasers thereof under this Agreement.

(c)

Payment for the Securities to be purchased on the Closing Date or the Additional Closing Date, as the case may be, shall be made

against delivery to the Representative for the accounts of the several Underwriters of the Securities to be purchased on such date with

any transfer taxes payable in connection with the sale of such Securities duly paid by the Company. Delivery of the Securities shall be

made through the facilities of The Depository Trust Company unless the Representative shall otherwise instruct. The Warrants will be made

available for inspection by the Representative on the business day prior to the Closing Date.

(d)

The Company acknowledges and agrees that each Underwriter is acting solely in the capacity of an arm’s length contractual

counterparty to the Company with respect to the public offering of Securities contemplated hereby (including in connection with determining

the terms of the public offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. The

Company further acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to this Agreement, including the determination

of the offering price of the Securities, and any related discounts and commissions, does not constitute a recommendation, investment advice,

or solicitation of any actions by any Underwriter, (b) no Underwriter has assumed and none will assume an advisory or fiduciary responsibility

in favor of the Company with respect to the public offering of the Securities or the process leading thereto (irrespective of whether

any Underwriter has advised or is currently advising the Company on other matters) and no Underwriter has any obligation to the Company

with respect to the public offering of the Securities except the obligations expressly set forth in this Agreement, (c) the Underwriters

and their affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, (d)

the Underwriters have not provided any legal, accounting, regulatory, investment or tax advice with respect to the public offering of

the Securities and the Company has consulted its own respective legal, accounting, financial, regulatory and tax advisors to the extent

it deemed appropriate and (e) none of the activities of the Underwriters in connection with the transactions contemplated herein constitutes

a recommendation, investment advice or solicitation of any action by any Underwriter with respect to any entity or natural person. Any

review by the Underwriters of the Company, the transactions contemplated hereby or other matters relating to such transactions will be

performed solely for the benefit of the Underwriters and shall not be on behalf of the Company.

Representations and Warranties of the Company. The Company represents and warrants to each Underwriter that:

(a)

Preliminary Prospectus. No order preventing or suspending the use of any preliminary prospectus has been issued by the Commission,

and each preliminary prospectus included in the Pricing Disclosure Package, if any, at the time of filing thereof, complied in all material

respects with the Securities Act, and no preliminary prospectus, if any, at the time of filing thereof, contained any untrue statement

of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances

under which they were made, not misleading; provided that the Company makes no representation or warranty with respect to any statements

or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing

by the Representative expressly for use in any preliminary prospectus, it being understood and agreed that the only such information furnished

by the Representative consists of the information described as such in Section 7(b) hereof.

(b)

Pricing Disclosure Package. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date

and any Additional Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in

order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that

the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with

information relating to any Underwriter furnished to the Company in writing by the Representative expressly for use in such Pricing Disclosure

Package, it being understood and agreed that the only such information furnished by the Representative consists of the information described

as such in Section 7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure

Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in the Prospectus

has been omitted therefrom.

(c)

Issuer Free Writing Prospectus. Other than the Registration Statement, the preliminary prospectus, if any, and the Prospectus,

the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made,

used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any “written communication”

(as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Securities

(each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i) below)

an “Issuer Free Writing Prospectus”) other than (i) any document not constituting a prospectus pursuant to Section

2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii) the documents listed on Annex A(a) hereto, each electronic

road show and any other written communications approved in writing in advance by the Representative. Each such Issuer Free Writing Prospectus

complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in

accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in the Registration

Statement or the Prospectus, including any document incorporated by reference therein and when taken together with any preliminary prospectus

accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date and any Additional

Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the

statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company makes

no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or any preliminary

prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by the

Representative expressly for use in such Issuer Free Writing Prospectus or any preliminary prospectus, it being understood and agreed

that the only such information furnished by the Representative consists of the information described as such in Section 7(b) hereof.

(d)

Registration Statement and Prospectus. The Company meets the requirements for use of Form S-3 under the Securities Act.

The Registration Statement and any post-effective amendment thereto has been declared effective by the Commission. No order suspending

the effectiveness of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section

8A of the Securities Act against the Company or related to the public offering of the Securities has been initiated or, to the knowledge

of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective

amendment thereto, each deemed effective date with respect to the Underwriters pursuant to Rule 430B(f)(2) under the Securities Act, at

the Applicable Time, complied and will comply in all material respects with the requirements of the Securities Act. Each preliminary prospectus,

if any, the Prospectus and any amendment or supplement thereto, at the time each was filed with the Commission, and, in each case, at

the Applicable Time, and the Closing Date and any Additional Closing Date complied and will comply in all material respects with the requirements

of the Securities Act.

The Registration Statement and any post-effective

amendment did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated

therein or necessary in order to make the statements therein not misleading; and as of the date of each preliminary prospectus, if any,

and any amendment or supplement thereto and as of the Closing Date and any Additional Closing Date each preliminary prospectus, if any,

will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,

in the light of the circumstances under which they were made, not misleading; provided that the Company makes no representation

and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter

furnished to the Company in writing by the Representative expressly for use in the Registration Statement and the Prospectus and any amendment

or supplement thereto, it being understood and agreed that the only such information furnished by the Representative consists of the information

described as such in Section 7(b) hereof.

The documents incorporated or deemed to be

incorporated by reference in the Registration Statement and the Prospectus, when they became effective or at the time they were filed

or hereafter are filed with the Commission, complied and will comply in all material respects with the requirements of the Exchange Act.

The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Pricing Disclosure Package and

the Prospectus, at the time the Registration Statement became effective or when such documents incorporated by reference were filed with

the Commission, as the case may be, when read together with the other information in the Registration Statement, the Pricing Disclosure

Package or the Prospectus, as the case may be, did not and will not include an untrue statement of a material fact or omit to state a

material fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which

they were made with respect to the Pricing Disclosure Package or Prospectus, not misleading.

(e)

Financial Statements. The financial statements (including the related notes thereto) of the Company and its subsidiaries

included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material

respects with the applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly in all material

respects the consolidated financial position of the Company and its subsidiaries as of the dates indicated and the results of their operations

and the changes in their cash flows for the periods specified; such financial statements have been prepared in conformity with generally

accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods covered

thereby, except in the case of unaudited financial statements, which are subject to normal year-end adjustments and do not contain certain

footnotes as permitted by the applicable rules of the Commission; and any supporting schedules included or incorporated by reference in

the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial

information included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has

been derived from the accounting records of the Company and its subsidiaries and presents fairly in all material respects the information

shown thereby. The interactive data in eXtensible Business Reporting Language incorporated by reference in the Registration Statement,

the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects and has been prepared

in accordance with the Commission’s rules and guidelines applicable thereto.

(f)

No Material Adverse Change. Since the date of the most recent financial statements of the Company included in the Registration

Statement, the Pricing Disclosure Package and the Prospectus, (i) there has not been any material change in the share capital (other than

the issuance of Common Shares upon exercise of share options and warrants, the vesting or settlement of restricted share units (whether

outstanding as of the date of such financial statements or granted thereafter under existing equity incentive plans) or the conversion

of preferred shares described as outstanding in, and the grant of options and awards under existing equity incentive plans described in,

the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt or long-term debt of the Company or its

subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of

share capital, or any material adverse change, or any development involving a prospective material adverse change, in or affecting the

business, properties, management, financial position, shareholders’ equity, results of operations or prospects of the Company and

its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement

(whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred

any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither

the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its

subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or

from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority,

except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(g)

Organization and Good Standing. The Company has been duly organized and is validly existing and in good standing under the

laws of its jurisdiction of organization, is duly qualified to do business and is in good standing in each jurisdiction in which its ownership

or lease of property or the conduct of its business requires such qualification, and has all power and authority necessary to own or hold

its properties and to conduct the businesses in which it is engaged, except where the failure to be so qualified or in good standing or

have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on

the business, properties, management, financial position, shareholders’ equity, results of operations or prospects of the Company

and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a “Material

Adverse Effect”). Each of the Company’s subsidiaries has been duly incorporated or organized, as the case may be, and

is validly existing as a corporation or other entity, as applicable, in good standing under the laws of the jurisdiction of its incorporation

or organization and has the power and authority (corporate or other) to own, lease and operate its properties and to conduct its business

as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to be so qualified

or in good standing would not, individually or in the aggregate, result in a Material Adverse Effect. Each of the Company’s subsidiaries

is duly qualified as a foreign corporation or other entity, as applicable, to transact business and is in good standing in each jurisdiction

in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except

where the failure to be so qualified or in good standing would not, individually or in the aggregate, result in a Material Adverse Effect.

All of the share capital or other equity or ownership interests of each of the Company’s subsidiaries have been duly authorized

and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of

any security interest, mortgage, pledge, lien, encumbrance or adverse claim. None of the outstanding capital stock or equity interest

in any subsidiary was issued in violation of preemptive or similar rights of any security holder of such subsidiary. The constitutive

or organizational documents of each of the subsidiaries comply in all material respects with the requirements of applicable laws of its

jurisdiction of incorporation or organization and are in full force and effect. The Company does not own or control, directly or indirectly,

any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Company’s most recent Annual

Report on Form 10-K filed with the Commission.

(h)

Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure

Package and the Prospectus under the heading “Description of Capital Shares”; all the outstanding share capital of the Company

has been duly and validly authorized and issued and is fully paid and non-assessable and is not subject to any pre-emptive or similar

rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the Registration Statement, the

Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, pre-emptive rights), rights

of first refusal, warrants or options to acquire, or instruments convertible into or exchangeable for, any share capital or other equity

interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating

to the issuance of any share capital of the Company or any of its subsidiaries, any such convertible or exchangeable securities or any

such rights, warrants or options; and the share capital of the Company conforms in all material respects to the description thereof contained

in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(i)

Share Options. With respect to the share options (the “Share Options”) granted pursuant to the share-based

compensation plans of the Company (the “Company Share Plans”), (i) each Share Option intended to qualify as an “incentive

stock option” under Section 422 of the Internal Revenue Code of 1986, as amended (the “Code”) so qualifies, (ii)

each grant of a Share Option was duly authorized no later than the date on which the grant of such Share Option was by its terms to be

effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted

and authorized committee thereof) and any required shareholder approval by the necessary number of votes or written consents, and the

award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii) each such grant was made in

accordance with the terms of the Company Share Plans and all other applicable laws and regulatory rules or requirements and (iv) each

such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company.

Each Company Share Plan is accurately described in all material respects in the Registration Statement, the Pricing Disclosure Package

and the Prospectus. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company granting,

Share Options, prior to, or otherwise coordinating the grant of Share Options with, the release or other public announcement of material

information regarding the Company or its results of operations or prospects.

(j)

Due Authorization. The Company has full right, power and authority to execute and deliver this Agreement and the Warrants

and to perform its obligations under each of the Agreement and the Warrants, respectively; and all action required to be taken for the

due and proper authorization, execution and delivery by it of this Agreement and the Warrants and the consummation by it of the transactions

contemplated by each of the Agreement and the Warrants, respectively, has been duly and validly taken.

(k)

Underwriting Agreement. This Agreement has been duly authorized, executed and delivered by the Company.

(l)

The Securities. The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company and,

when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will

conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus;

and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. The Warrants

have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and binding agreements of the

Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy,

insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general

equitable principles. The Warrant Shares have been duly authorized and reserved for issuance upon exercise of the Warrants pursuant to

the terms of the Warrants in a number sufficient to meet the current exercise requirements, and when issued and delivered upon valid exercise

in accordance with the terms of the Warrants will be validly issued, fully paid and non-assessable, will conform in all material respects

to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will be issued

in compliance with all applicable state, federal and foreign securities laws and will not be issued in violation of or subject to any

preemptive or similar right that entitles any person to acquire any security from the Company.

(m)

Listing. The Common Shares are registered pursuant to Section 12(b) or 12(g) of the Exchange Act and the Common Shares

are listed on the Nasdaq Capital Market, and the Company has taken no action designed to, or likely to have the effect of, terminating

the registration of the Common Shares under the Exchange Act or delisting the Common Shares from the Nasdaq Capital Market. Except as

disclosed in the Registration Statement or Prospectus, the Company has not received any notification that the Commission or The Nasdaq

Stock Market LLC is contemplating terminating such registration or listing. To the Company’s knowledge, and except as otherwise

described in the Registration Statement or Prospectus, the Company is in compliance with all applicable listing requirements of The Nasdaq

Stock Market LLC.

(n)

No Violation or Default. Neither the Company nor any of its subsidiaries is (i) in

violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice

or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained

in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries

is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any

of its subsidiaries is subject; or (iii) in violation of any law or statute or any judgment, order, rule or regulation of any court

or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii)

above, for any such default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse

Effect.

(o)

No Conflicts. The execution, delivery and performance by the Company of this Agreement

and the Warrants, the issuance and sale of the Securities and the consummation of the transactions contemplated by this Agreement and

the Warrants or the Pricing Disclosure Package and the Prospectus will not (i) conflict with or result in a breach or violation

of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result

in the creation or imposition of any lien, charge or encumbrance upon any property, right or assets of the Company or any of its subsidiaries

pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its

subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property, right or assets of

the Company or any of its subsidiaries is subject, (ii) result in any violation of the provisions of the charter or by-laws or similar

organizational documents of the Company or any of its subsidiaries or (iii) result in the violation of any law or statute or any judgment,

order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii)

above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate,

reasonably be expected to have a Material Adverse Effect.

(p)

No Consents Required. No consent, filing, approval, authorization, order, license, registration or qualification of or with

any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company

of this Agreement and the Warrants, the issuance and sale of the Securities and the consummation

of the transactions contemplated by this Agreement and the Warrants, except for the registration

of the Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications

as may be required by the Financial Industry Regulatory Authority, Inc. (“FINRA”), the Nasdaq Capital Market and under

applicable state securities laws in connection with the purchase and distribution of the Securities by the Underwriters, and such as have

been obtained or made by the Company and its subsidiaries and are in full force and effect.

(q)

Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, demands, claims, suits, arbitrations,

inquiries or proceedings (“Actions”) pending to which the Company or any of its subsidiaries is or may reasonably be

expected to become a party or to which any property of the Company or any of its subsidiaries is or may reasonably be expected to become

the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably

be expected to have a Material Adverse Effect; to the knowledge of the Company, no such Actions are threatened or contemplated by any

governmental or regulatory authority or threatened by others; and (i) there are no current or pending Actions that are required under

the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described

in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii) there are no statutes, regulations or contracts

or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the

Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement

or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(r)

Independent Accountants. MNP LLP, who has certified certain financial statements of the Company, is an independent registered

public accounting firm with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public

Company Accounting Oversight Board (United States) and as required by the Securities Act and the Exchange Act.

(s)

Title to Real and Personal Property. The Company and its subsidiaries have good and marketable title in fee simple (in the

case of real property) to, or have valid rights to lease or otherwise use, all items of real and personal property and assets that are

material to the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims

and defects and imperfections of title except those that (i) do not materially interfere with the use made and proposed to be made of

such property by the Company or its subsidiaries or (ii) would not reasonably be expected, individually or in the aggregate, to have a

Material Adverse Effect.

(t)

Title to Intellectual Property. The Company and its subsidiaries own, or possess valid

and enforceable licensed rights to use, or can acquire on reasonable terms, all material patents, patent applications, trademarks, service

marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights, internet domain

names, copyrights, works of authorship, licenses, proprietary information and know-how (including trade secrets and other unpatented and/or

unpatentable proprietary or confidential information, systems or procedures) necessary for the conduct of their respective businesses

as currently conducted and as proposed to be conducted (collectively, “Intellectual Property”), and the conduct of

their respective businesses does not and will not infringe, misappropriate or otherwise conflict in any material respect with any such

rights of others. The Intellectual Property has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable,

in whole or in part, and the Company is unaware of any facts which would form a reasonable basis

for any such adjudication. Neither the Company nor any of its subsidiaries has received any

notice of any claim of infringement, misappropriation or conflict with any intellectual property rights of another which would, singly

or in the aggregate, result in a Material Adverse Effect, and the Company is unaware of any facts which would form a reasonable basis

for any such notice or claim. To the Company’s knowledge and except for customary reversionary rights of third-party licensors with

respect to Intellectual Property that is disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus (“Disclosure

Documents”) as owned by or licensed to the Company or any of its subsidiaries: (i) there are no third parties who have rights

to any Intellectual Property and (ii) there is no infringement by third parties of any Intellectual Property. Except as disclosed

in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no pending

or, to the Company’s knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company’s or any

of its subsidiaries’ rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable

basis for any such action, suit, proceeding or claim; (B) challenging the validity, enforceability or scope of any Intellectual Property,

and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting

that the Company or any of its subsidiaries infringes, misappropriates, or otherwise violates, or would, upon the commercialization of

any product or service described in the Disclosure Documents as under development, infringe, misappropriate or otherwise violate, any

intellectual property rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action,

suit, proceeding or claim.

The Company and its subsidiaries have materially complied with the terms of each agreement pursuant to which

Intellectual Property has been licensed to the Company or any of its subsidiaries, and all such agreements are in full force and effect.

To the Company’s knowledge, there are no material defects in any of the patents or patent applications included in the Intellectual

Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual

Property, including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention

assignments with their employees. The duty of candor and good faith as required by the United States Patent and Trademark Office during

the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied with; and

in all foreign offices having similar requirements, all such requirements have been complied with. To the Company’s knowledge, none

of the Intellectual Property or technology (including information technology and outsourced arrangements) employed by the Company or its

subsidiaries has been obtained or is being used by the Company or its subsidiaries in violation of any contractual obligation binding

on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in violation of the rights

of any persons. The product candidates described in the Disclosure Documents as under development

by the Company or any subsidiary fall within the scope of the claims of one or more patents or patent applications owned by, or exclusively

licensed to, the Company or any subsidiary.

(u)

Trade Secrets. The Company and its subsidiaries have taken reasonable and customary actions to protect their rights in and

prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including confidential source

code, ideas, research and development information, know-how, formulas, compositions, technical data, designs, drawings, specifications,

research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and information,

pricing and cost information, business and marketing plans and proposals) owned by the Company or its subsidiaries, and, to the knowledge

of the Company, there has been no unauthorized use or disclosure.

(v)

IT Assets. Except as could not reasonably be expected to have a Material Adverse Effect (i) the computers, software,

servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the

Company (excluding any public networks) (collectively, the “IT Assets”) operate and perform as is necessary for the

operation of the business of the Company as currently conducted and as proposed to be conducted as described in the Registration Statement,

the Pricing Disclosure Package and the Prospectus, and (ii) such IT Assets are not infected by viruses, disabling code or other harmful

code. The Company and its subsidiaries have implemented and maintained all reasonably necessary controls, policies, procedures, and safeguards

to maintain and protect their confidential information and the integrity, continuous operation, redundancy and security of all IT Assets

and data (including all Personal Data (defined below) that is sensitive, confidential or regulated data (“Confidential Data”)

used in connection with their businesses, and there have been no material breaches, violations, outages or unauthorized uses of or accesses

to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents

under internal review or investigations relating to the same.

(w)

Compliance with Data Privacy Laws. The Company and its subsidiaries are, and at all prior times were, in material compliance

with all applicable state and federal data privacy and security laws and regulations, including without limitation HIPAA (as defined below),

and the Company and its subsidiaries have taken commercially reasonable actions to prepare to comply with, and since May 25, 2018, have

been and currently are in compliance with, the European Union General Data Protection Regulation (“GDPR”) (EU 2016/679)

(collectively, the “Privacy Laws”). To ensure compliance with the Privacy Laws, the Company and its subsidiaries have

in place, comply with, and take appropriate steps reasonably designed to ensure compliance in all material respects with their policies

and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and analysis of Personal

Data (the “Policies”). The Company and its subsidiaries have at all times made all disclosures to users or customers

required by applicable laws and regulatory rules or requirements, and none of such disclosures made or contained in any Policy have, to

the knowledge of the Company, been inaccurate or in violation of any applicable laws and regulatory rules or requirements in any material

respect. The Company further certifies that neither it nor any subsidiary: (i) has received notice of any actual or potential liability

under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that

would reasonably be expected to result in any such notice; (ii) is currently conducting or paying for, in whole or in part, any investigation,

remediation, or other corrective action pursuant to any Privacy Law; or (iii) is a party to any order, decree, or agreement that imposes

any obligation or liability under any Privacy Law.

(x)

FDA, Health Canada and USDA Compliance. The Company and its subsidiaries: (A) are and at all times have been in compliance

with all statutes, rules or regulations of the FDA, Health Canada, USDA and other comparable governmental entities applicable to the ownership,

testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage,

import, export or disposal of any product under development, manufactured or distributed by the Company or its subsidiaries (“Applicable

Laws”), except where such noncompliance would not singly or in the aggregate reasonably be expected to result in a Material

Adverse Effect; (B) possess all material licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements

or amendments thereto required by any such Applicable Laws (“Authorizations”) and such Authorizations are valid and

in full force and effect and neither the Company nor any of its subsidiaries is in material violation of any term of any such Authorizations;

and (C) have not received written notice that the FDA, Health Canada or any governmental entity has taken, is taking or intends to take

action to limit, suspend, modify or revoke any Authorizations and have no knowledge that the FDA, Health Canada or any governmental entity

is considering such action.

(y)

Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials conducted by or, to the

Company’s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance

with Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act; except to the extent disclosed in the Registration

Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of

which reasonably call into question the study, test, or trial results described or referred to in the Registration Statement, the Pricing

Disclosure Package and the Prospectus when viewed in the context in which such results are described and the state of development; and,

except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received

any written notices or correspondence from the FDA, Health Canada or any governmental entity requiring the termination or suspension of

any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications

with respect to modifications in connection with the design and implementation of such trials.

(z)

Compliance with Health Care Laws. The Company and its subsidiaries have been at all times in compliance with all Health Care Laws,

except where such noncompliance would not singly or in the aggregate reasonably be expected to result in a Material Adverse Effect. For

purposes of this Agreement, “Health Care Laws” means: (i) the Federal Food, Drug, and Cosmetic Act (21 U.S.C. Section 301

et seq.) and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud and abuse

laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Civil False Claims Act (31

U.S.C. Section 3729 et seq.), the Criminal False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections 286 and 287, the health

care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996 (“HIPAA”)

(42 U.S.C. Section 1320d et seq.), the Stark Law (42 U.S.C. Section 1395nn), the civil monetary penalties law (42 U.S.C. Section 1320a-7a),

the exclusions law (42 U.S.C. Section 1320a-7), the Physician Payments Sunshine Act (42 U.S.C. Section 1320a-7h), and applicable laws

governing government funded or sponsored healthcare programs; (iii) HIPAA, as amended by the Health Information Technology for Economic

and Clinical Health Act (42 U.S.C. Section 17921 et seq.), (iv) Medicare (Title XVIII of the Social Security Act), Medicaid (Title XIX

of the Social Security Act), (v) the Public Health Service Act (42 U.S.C. § 201 et seq.), (vi) the regulations promulgated pursuant

to such statutes and any state or foreign counterpart thereof, (vii) any similar applicable local, state, federal, national, supranational

and foreign laws, relating to the regulation of the Company, and (viii) any and all other applicable health care laws and regulations.Neither

the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,

arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging that any product

operation or activity is in violation of any Health Care Laws nor, to the Company’s knowledge, is any such claim, action, suit,

proceeding, hearing, enforcement, investigation, arbitration or other action threatened. The Company and its subsidiaries have filed,

maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments

as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements

or amendments were complete and accurate on the date filed in all respects (or were corrected or supplemented by a subsequent submission),

except where such failure would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse Effect. Neither

the Company nor any of its subsidiaries is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement

orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its

subsidiaries nor any of their respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation

in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry,

investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

(aa)

No Undisclosed Relationships. No relationship, direct or indirect, exists between or among the Company, on the one hand,

and the directors, officers, shareholders, customers, suppliers or other affiliates of the Company, on the other, that is required by

the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents

and in the Pricing Disclosure Package.

(bb)

Investment Company Act. The Company is not and, after giving effect to the public offering and sale of the Securities and

the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus,

will not be required to register as an “investment company” or an entity “controlled” by an “investment

company” within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder

(collectively, the “Investment Company Act”).

(cc)

Taxes. The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns

required to be paid or filed through the date hereof, except for those taxes and tax returns whose failure to pay or file would not reasonably

be expected to have a Material Adverse Effect; and, except as otherwise disclosed in the Registration Statement, the Pricing Disclosure

Package or the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company

or any of its subsidiaries or any of their respective properties or assets that has had or would reasonably be expected to have a Material

Adverse Effect, except for any tax deficiency being contested in good faith and for which appropriate reserves have been provided in accordance

with GAAP. No stamp or other issuance or transfer taxes, duties or similar charges are payable by, or required to be withheld on behalf

of, the Underwriters to Canada or any political subdivision or taxing authority thereof or therein in connection with (i) the execution,

delivery or performance of this Agreement or the Warrants or (ii) the issuance, sale or delivery of the Securities to the Underwriters

or resale of Securities by an Underwriter to U.S. residents.

(dd)

Licenses and Permits. The Company and its subsidiaries possess all licenses, certificates, permits and

other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental

or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective

businesses as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus, except where the failure

to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and,

except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor any of its

subsidiaries has received written notice of any revocation or modification of any such license, certificate, permit or authorization or

has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course, except

where such revocation or modification would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

No party granting any such licenses, certificates, permits and other authorizations has taken any action to limit, suspend or revoke the

same in any respect, except where such action would not, singly or in the aggregate, reasonably be expected to result in a Material Adverse

Effect. The Company and its subsidiaries have filed, obtained, maintained or submitted all reports, documents, forms, notices, applications,

records, claims, submissions and supplements or amendments as required and that all such reports, documents, forms, notices, applications,

records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented

by a subsequent submission) as required for maintenance of their licenses, certificates, permits and other authorizations that are necessary

for the conduct of their respective businesses, except where such non-compliance would not, individually or in the aggregate, reasonably

be expected to have a Material Adverse Effect.

(ee)

No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or,

to the knowledge of the Company, is threatened, and neither the Company nor any of its subsidiaries is aware of any existing or imminent

labor disturbance by, or dispute with, the employees of any of its principal suppliers, contractors or customers, except in any event

as would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any

notice of cancellation or termination with respect to any collective bargaining agreement that is material to the Company and its subsidiaries

taken as a whole.

(ff)

Certain Environmental Matters. (i) The Company and its subsidiaries (x) are in compliance with all, and have not violated

any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and other

legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources,

hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have

received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals

required of them under any Environmental Laws to conduct their respective businesses; and (z) have not received written notice of any

actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including

for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants,

and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii) there are no

costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each

of (i) and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse

Effect; and (iii) (x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company

or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such proceeding regarding

which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y) the Company is not aware of any facts

or issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous

or toxic substances or wastes, pollutants or contaminants, that would, individually or in the aggregate, reasonably be expected to have

a Material Adverse Effect, and (z) neither the Company nor any of its subsidiaries anticipates material capital expenditures relating

to any Environmental Laws.

(gg)

Hazardous Materials. There has been no storage, generation, transportation, use, handling, treatment, Release or threat

of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company,

any other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably

be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or

any of its subsidiaries, or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner

or amount or to a location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation

or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. “Hazardous

Materials” means any material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in

any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos

and asbestos containing materials, naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise

to liability under any Environmental Law. “Release” means any spilling, leaking, seepage, pumping, pouring, emitting, emptying,

discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment,

or in, into from or through any building or structure.

(hh)

Compliance with ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income

Security Act of 1974, as amended (“ERISA”), for which the Company, any of its subsidiaries, or any member of its “Controlled

Group” (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of

Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section 414(b), (c), (m)

or (o) of the Code) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and

the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii) no prohibited

transaction, within the meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan, excluding

transactions effected pursuant to a statutory or administrative exemption; (iii) for each Plan that is subject to the funding rules of

Section 412 of the Code or Section 302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy

the minimum funding standards (within the meaning of Section 302 of ERISA or Section 412 of the Code) applicable to such Plan; (iv) no

Plan is, or is reasonably expected to be, in “at risk status” (within the meaning of Section 303(i) of ERISA) and no Plan

that is a “multiemployer plan” within the meaning of Section 4001(a)(3) of ERISA is in “endangered status” or

“critical status” (within the meaning of Sections 304 and 305 of ERISA); (v) the fair market value of the assets of each Plan

exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi)

no “reportable event” (within the meaning of Section 4043(c) of ERISA and the regulations promulgated thereunder) has occurred

or is reasonably expected to occur; (vii) each Plan that is intended to be qualified under Section 401(a) of the Code is so qualified,

and, to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would reasonably be expected

to cause the loss of such qualification; (viii) neither the Company nor any of its subsidiaries nor any member of the Controlled Group

has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums

to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer

plan” within the meaning of Section 4001(a)(3) of ERISA); and (ix) none of the following events has occurred or is reasonably likely

to occur: (A) a material increase in the aggregate amount of contributions required to be made to all Plans by the Company, its subsidiaries

or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount

of such contributions made in the Company’s and its Controlled Group affiliates’ most recently completed fiscal year; or (B)

a material increase in the Company’s “accumulated post-retirement benefit obligations” (within the meaning of Accounting

Standards Codification Topic 715-60) compared to the amount of such obligations in the Company’s most recently completed fiscal

year, except in each case with respect to the events or conditions set forth in (i) through (ix) hereof, as would not, individually or

in the aggregate, have a Material Adverse Effect.

(ii)

Disclosure Controls. The Company maintains an effective system of “disclosure controls and procedures” (as defined

in Rule 13a-15(e) of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to ensure that

material information relating to the Company, including its consolidated subsidiaries, required to be disclosed by the Company in reports

that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the

Commission’s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated

to the Company’s management as appropriate to allow timely decisions regarding required disclosure. The Company has carried out

evaluations of the effectiveness of its disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act through June

30, 2026.

(jj)

Accounting Controls. The Company and each of its subsidiaries make and keep accurate books and records and maintain systems

of “internal control over financial reporting” (as defined in Rule 13a-15(f) of the Exchange Act) that are designed to comply

with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive

and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of

financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting

principles, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions

are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as necessary to

permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain asset accountability;

(iii) access to assets is permitted only in accordance with management’s general or specific authorization; and (iv) the recorded

accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to

any differences; and (v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration

Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material respects and is

prepared in accordance with the Commission’s rules and guidelines applicable thereto. There are no material weaknesses in the Company’s

internal controls. The Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of:

(i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which

have adversely affected or are reasonably likely to adversely affect the Company’s ability to record, process, summarize and report

financial information; and (ii) any fraud, whether or not material, that involves management or other employees who have a significant

role in the Company’s internal controls over financial reporting.

(kk)

Insurance. The Company and its subsidiaries have insurance covering their respective properties, operations, personnel and

businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are

generally maintained by similarly situated companies and which the Company believes are reasonably adequate to protect the Company, its

subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer

or agent of such insurer that capital improvements or other expenditures are required or necessary to be made in order to continue such

insurance or (ii) any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires

or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.

(ll)

No Unlawful Payments. Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company

or any of its subsidiaries, nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf

of the Company or any of its subsidiaries, has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other

unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of any

direct or indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee, including of

any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for

or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is

in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing

the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under

the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption laws; or (iv) made, offered, agreed,

requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff,

influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain

and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance with all applicable

anti-bribery and anti-corruption laws.

(mm)

Compliance with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted

at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign

Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or its

subsidiaries conduct business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued,

administered or enforced by any governmental or regulatory agency (collectively, the “Anti-Money Laundering Laws”)

and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving

the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company,

threatened.

(nn)

No Conflicts with Sanctions Laws. Neither the Company nor any of its subsidiaries, directors, officers or employees, nor,

to the knowledge of the Company, any agent, or affiliate or other person associated with or acting on behalf of the Company or any of

its subsidiaries, is currently the subject or the target of any sanctions administered or enforced by the U.S. Government, (including,

without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including,

without limitation, the designation as a “specially designated national” or “blocked person”), the United Nations

Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”),

nor is the Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target

of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, and certain regions of Ukraine (Crimea, Donetsk People’s

Republic, Luhansk People’s Republic, Kherson and Zaporizhzhia) (each, a “Sanctioned Country”); and the Company

will not directly or indirectly use the proceeds of the public offering of the Securities hereunder, or lend, contribute or otherwise

make available such proceeds to any subsidiary, joint venture partner or other person or entity (i) to fund or facilitate any activities

of or business with any person that, at the time of such funding or facilitation, is the subject or the target of Sanctions, (ii) to fund

or facilitate any activities of or business in any Sanctioned Country or (iii) in any other manner that will result in a violation by

any person (including any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions.

Since April 24, 2019, neither the Company nor any of its subsidiaries has knowingly engaged in and neither is now knowingly engaged in

any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions

or with any Sanctioned Country.

(oo)

No Broker’s Fees. The Company is not a party to any contract, agreement or understanding with any person (other than

this Agreement) that would give rise to a valid claim against the Company or any Underwriter for a brokerage commission, finder’s

fee or like payment in connection with the public offering and sale of the Securities.

(pp)

No Registration Rights. No person has the right to require the Company to register any securities for sale under the Securities

Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Securities, except for such

rights as have duly been waived.

(qq)

No Stabilization. Neither the Company nor, to the Company’s knowledge, affiliates have taken, directly

or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of

the price of the Securities.

(rr)

Margin Rules. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the

Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation

T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors.

(ss)

Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and Section

21E of the Exchange Act) contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed

without a reasonable basis or has been disclosed other than in good faith.

(tt)

Statistical and Market Data. Nothing has come to the attention of the Company that has caused the Company to believe that the

statistical and market-related data included in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus

is not based on or derived from sources that are reliable and accurate in all material respects.

(uu)

Sarbanes-Oxley Act. There is and has been no failure on the part of the Company or any of the Company’s directors

or officers, in their capacities as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and

regulations promulgated in connection therewith (the “Sarbanes-Oxley Act”), including Section 402 related to loans.

(vv)

Status under the Securities Act. At the time of filing the Registration Statement and any post-effective amendment thereto,

at the earliest time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule

164(h)(2) under the Securities Act) of the Securities and at the date hereof, the Company was not and is not an “ineligible issuer,”

as defined in Rule 405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule 456(b)(1)

under the Securities Act or will pay such fee within the time period required by such rule (without giving effect to the proviso therein)

and in any event prior to the Closing Date and any Additional Closing Date.

(ww)

No Ratings. There are (and prior to the Closing Date and any Additional Closing Date, will be) no debt securities, convertible

securities or preferred share issued or guaranteed by the Company that are rated by a “nationally recognized statistical rating

organization,” as such term is defined in Section 3(a)(62) of the Exchange Act.

(xx)

No Outstanding Loans or Other Extensions of Credit. The Company does not have any outstanding extension of credit, in the

form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions

of credit as are expressly permitted by Section 13(k) of the Exchange Act.

(yy)

Cybersecurity. The Company’s and its subsidiaries’ information technology assets and equipment, computers, systems,

networks, hardware, software, websites, applications, and databases (collectively, “IT Systems”) are adequate for,

and operate and perform in all material respects as required in connection with the operation of the business of the Company and its subsidiaries

as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.

The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures and safeguards

to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all

IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (“Personal Data”),

used in connection with their businesses. There have been no material breaches, violations, outages or unauthorized uses of or accesses

to same, except for those that have been remedied without material cost or liability or the duty to notify any other person, nor any incidents

under internal review or investigations relating to the same. The Company and its subsidiaries are presently in material compliance with

all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory

authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Personal Data and to the

protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation or modification.

(zz)

Dividend Restrictions. No subsidiary of the Company is prohibited or restricted, directly or indirectly, from paying dividends

to the Company, or from making any other distribution with respect to such subsidiary’s equity securities or from repaying to the

Company or any other subsidiary of the Company any amounts that may from time to time become due under any loans or advances to such subsidiary

from the Company or from transferring any property or assets to the Company or to any other subsidiary.

(aaa)

Outbound Investment Security Program. Neither the Company nor any of its subsidiaries is a “covered foreign person”,

as that term is defined in 31 C.F.R. § 850.209. Neither the Company nor any of its subsidiaries currently engages, or has plans to

engage, directly or indirectly, in a “covered activity”, as that term is defined in 31 C.F.R. § 850.208 (“Covered

Activity”). The Company does not have any joint ventures that engage in or plan to engage in any Covered Activity. The Company

also does not, directly or indirectly, hold a board seat on, have a voting or equity interest in, or have any contractual power to direct

or cause the direction of the management or policies of any person or persons that engages or plans to engage in any Covered Activity.

(bbb)

Immunity from Jurisdiction. Neither the Company nor any of its subsidiaries nor any of its or their properties or assets

has any immunity from the jurisdiction of any court or from any legal process (whether through service or notice, attachment prior to

judgment, attachment in aid of execution or otherwise) under the laws of Canada and the laws of the Province of British Columbia. The

irrevocable and unconditional waiver and agreement of the Company contained in this Agreement not to plead or claim any such immunity

in any legal action, suit or proceeding based on this Agreement is valid and binding under the laws of Canada and the laws of the Province

of British Columbia. The choice of the law of the State of New York as the governing law of this Agreement is a valid choice of law under

the laws of Canada, and the Company is not aware of any basis for avoiding the choice on the grounds of British Columbia public policy,

as that term is understood under the laws of the Province of British Columbia and the laws of Canada applicable therein. The Company has

the power to submit, and has legally, validly, effectively and irrevocably submitted, to the personal jurisdiction of each New York State

and United States Federal court sitting in The City of New York and has validly and irrevocably waived any objection to the laying of

venue of any suit, action or proceeding brought in any such court.

(ccc)

Withholding Taxes. No withholding tax imposed under the federal laws of Canada will be payable in respect of any commission

or fee to be paid by the Company pursuant to this Agreement to the Underwriters that are “non-residents” within the meaning

of the Income Tax Act (Canada), provided any such commission or fee is payable in respect of services rendered by such Underwriters, wholly

outside of Canada and are performed in the ordinary course of business carried on by the Underwriters that includes the performance of

such services for a fee and such Underwriters deal at arm’s length with the Company within the meaning of the Income Tax Act (Canada)

and any such amount is reasonable in the circumstances.

Any certificate signed by any officer of

the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the Underwriters in connection with the public

offering, or the purchase and sale, of the Securities shall be deemed a representation and warranty by the Company to each Underwriter

as to the matters covered thereby.

Further Agreements of the Company. The Company covenants and agrees with the several Underwriters that:

(a)

Required Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule

424(b) and Rule 430B under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the

Securities Act; and will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered)

to the Representative in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement

in such quantities as the Representative may reasonably request.

(b)

Delivery of Copies. The Company will deliver, without charge, (i) to the Representative, four signed copies of the Registration

Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith or incorporated

by reference therein and documents incorporated or deemed to be incorporated by reference therein; and (ii) to the Representative (A)

a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B) during the Prospectus

Delivery Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and each Issuer

Free Writing Prospectus) as the Representative may reasonably request. As used herein, the term “Prospectus Delivery Period”

means such period of time after the first date of the public offering of the Securities as in the opinion of counsel for the Underwriters

a prospectus relating to the Securities is required by law to be delivered (or required to be delivered but for Rule 172 under the Securities

Act) in connection with sales of the Securities by the Underwriters or dealer.

(c)

Amendments or Supplements, Issuer Free Writing Prospectuses. Before preparing, using, authorizing, approving, referring

to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing

Disclosure Package or the Prospectus, the Company will furnish to the Representative and counsel for the Underwriters a copy of the proposed

Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize, approve, refer to or file any

such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representative reasonably objects.

(d)

Notice to the Representative. The Company will advise the Representative promptly, and confirm such advice in writing, (i)

when any amendment to the Registration Statement has been filed or becomes effective; (ii) when any supplement to the Pricing Disclosure

Package, the Prospectus, any Issuer Free Writing Prospectus, any amendment to the Prospectus has been filed or distributed; (iii) of any

request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus, including

any document incorporated by reference therein, or the receipt of any comments from the Commission relating to the Registration Statement

or any other request by the Commission for any additional information; (iv) of the issuance by the Commission or any other governmental

or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of

any preliminary prospectus, any of the Pricing Disclosure Package, the Prospectus or the initiation or, to the knowledge of the Company,

threatening of any proceeding for that purpose or pursuant to Section 8A of the Securities Act;

(v) of the occurrence of any event or

development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer Free

Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact

necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure

Package, or any such Issuer Free Writing Prospectus delivered to a purchaser, not misleading; and (vi) of the receipt by the Company of

any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation

or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its best efforts to prevent

the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any preliminary

prospectus, any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Securities and, if any

such order is issued, will obtain as soon as possible the withdrawal thereof.

(e)

Ongoing Compliance. (1) If during the Prospectus Delivery Period (i) any event or development shall occur or condition shall

exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit

to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus

is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Prospectus to comply with law, the Company

will promptly notify the Representative thereof and forthwith prepare and, subject to paragraph (c) above, file with the Commission and

furnish to the Representative and to such dealers as the Representative may designate such amendments or supplements to the Prospectus

as may be necessary so that the statements in the Prospectus as so amended or supplemented will not, in the light of the circumstances

existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2) if at any

time prior to the Closing Date and any Additional Closing Date (i) any event or development shall occur or condition shall exist as a

result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or

omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the

Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Pricing Disclosure

Package to comply with law, the Company will promptly notify the Representative thereof and forthwith prepare and, subject to paragraph

(c) above, file with the Commission (to the extent required) and furnish to the Representative and to such dealers as the Representative

may designate such amendments or supplements to the Pricing Disclosure Package as may be necessary so that the statements in the Pricing

Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package

is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with law.

(f)

Blue Sky Compliance. The Company will qualify the Securities for offer and sale under the securities or Blue Sky laws of

such jurisdictions as the Representative shall reasonably request and will continue such qualifications in effect so long as required

for distribution of the Securities; provided that the Company shall not be required to (i) qualify as a foreign corporation or

other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii) file any

general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not

otherwise so subject.

(g)

Earnings Statement. The Company will make generally available to its securityholders and the Underwriters as soon as practicable

an earnings statement that satisfies the provisions of Section 11(a) of the Securities Act and Rule 158 of the Commission promulgated

thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the “effective

date” (as defined in Rule 158) of the Registration Statement, provided that the Company will be deemed to have furnished

such statements to its securityholders and the Underwriters to the extent they are filed on the Commission’s Electronic Data Gathering,

Analysis and Retrieval system.

(h)

Clear Market. For a period of 90 days after the date of the Prospectus (the “Restricted Period”), the

Company will not, without the prior written consent of the Representative, (i) offer, pledge, sell, contract to sell, sell any option

or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer

or dispose of, directly or indirectly, or file with, or submit to, the Commission a registration statement under the Securities Act relating

to, any Common Shares or any securities convertible into or exercisable or exchangeable for Common Shares, (ii) enter into any swap, hedging

or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Common Shares or any such

other securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Shares or

such other securities, in cash or otherwise, (iii) effect a reverse share split, recapitalization, share consolidation, reclassification

or similar transaction affecting the outstanding Common Shares or (iv) publicly disclose the intention to do any of the foregoing, other

than (A) the Securities to be sold hereunder, (B) any Common Shares issued upon the exercise of options or the vesting or settlement of

restricted share units granted under Company Share Plans as described in the Registration Statement, the Pricing Disclosure Package and

the Prospectus, (C) any Common Shares issued upon the exercise of warrants or conversion of preferred shares outstanding on the date of

this Agreement and as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (D) any options and

other awards granted under a Company Share Plan described in the Registration Statement, the Pricing Disclosure Package and the Prospectus

and (E) the filing by the Company of any registration statement on Form S-8 or a successor form thereto relating to a Company Share Plan

described in the Registration Statement, the Pricing Disclosure Package and the Prospectus.

(i)

Use of Proceeds. The Company will apply the net proceeds from the sale of the Securities as described in each of the Registration

Statement, the Pricing Disclosure Package and the Prospectus under the heading “Use of Proceeds.”

(j)

No Stabilization. Neither the Company nor its affiliates will take, directly or indirectly,

without giving effect to the activities by the Underwriters, any action designed to or that could reasonably be expected to cause or result

in any stabilization or manipulation of the price of the Common Shares.

(k)

Exchange Listing. The Company will use its reasonable best efforts to list, subject to notice of issuance, the Shares and

Warrant Shares on the Nasdaq Capital Market.

(l)

Reports. During a period of three years from the date of this Agreement, the Company will furnish to the Representative,

as soon as commercially reasonable after the date they are available, copies of all reports or other communications (financial or other)

furnished to holders of the Securities, and copies of any reports and financial statements furnished to or filed with the Commission or

any national securities exchange or automatic quotation system; provided the Company will be deemed to have furnished such reports

and financial statements to the Representative to the extent they are filed on the Commission’s Electronic Data Gathering, Analysis,

and Retrieval system.

(m)

Record Retention. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer

Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act.

(n)

Registration Statement of Warrant Shares. The Company shall, at all times while any Warrants are outstanding, use its commercially

reasonable best efforts to maintain a registration statement covering the issue and sale of the Warrant Shares issuable upon exercise

of the Warrants such that the Warrant Shares, when issued, will not be subject to resale restrictions under the Securities Act except

to the extent that the Warrant Shares are owned by affiliates. The Company shall, at all times while any Warrants are outstanding, reserve

and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Shares, solely for the purpose

of enabling it to issue Warrant Shares upon exercise of such Warrants the number of Warrant Shares that are initially issuable and deliverable

upon the exercise of the then-outstanding Warrants.

(o)

FINRA Matters. All of the information provided to the Underwriters or to counsel for the Underwriters by the Company, its

counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company

in connection with the public offering of the Securities is true, complete, correct and compliant with FINRA’s rules and any letters,

filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct.

(p)

Parties to Lock-up Agreements. The Company has furnished to the Underwriters a letter agreement in the form attached hereto

as Exhibit C (the “Lock-up Agreement”) from each of the directors and officers of the Company. If any additional

persons shall become directors or executive officers of the Company prior to the end of the Restricted Period, the Company shall cause

each such person, prior to or contemporaneously with their appointment or election as a director or executive officer of the Company,

to execute and deliver to the Representative a Lock-up Agreement.

Certain Agreements of the Underwriters. Each Underwriter, severally and not jointly, hereby represents and agrees that:

(a)

It has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of,

refer to or participate in the planning for use of, any “free writing prospectus,” as defined in Rule 405 under the Securities

Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into

the Registration Statement and any press release issued by the Company) other than (i) a free writing prospectus that contains no “issuer

information” (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference)

in the preliminary prospectus, if any, or a previously filed Issuer Free Writing Prospectus, (ii) any Issuer Free Writing Prospectus listed

on Annex A(a) or prepared pursuant to Section 3(c) or Section 4(c) above (including any electronic road show), or (iii) any free writing

prospectus prepared by such Underwriter and approved by the Company in advance in writing.

(b)

It has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final

terms of the Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; provided

that the Representative may use a term sheet substantially in the form of Annex B hereto without the consent of the Company; provided

further that if the Representative uses such term sheet, it shall notify the Company and provide a copy of such term sheet to the

Company, prior to, or substantially concurrently with, the first use of such term sheet.

(c)

It is not subject to any pending proceeding under Section 8A of the Securities Act with respect to the public offering (and will

promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).

Conditions of the Underwriters’ Obligations. The respective obligations of the Underwriters to purchase the Underwritten

Shares, Pre-Funded Warrants and Underwritten Common Warrants on the Closing Date or the Option Shares and accompanying Option Common Warrants

on any Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and

other obligations hereunder and to the following additional conditions:

(a)

Registration Compliance; No Stop Order. No order suspending the effectiveness of the Registration Statement shall be in

effect, and no proceeding for such purpose or pursuant to Section 8A under the Securities Act shall be pending before or threatened by

the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with the Commission under the Securities

Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance

with Section 4(a) hereof; and all requests by the Commission for additional information shall have been complied with to the reasonable

satisfaction of the Representative.

(b)

Representations and Warranties. The representations and warranties of the Company contained herein shall be true and correct

on the date hereof and on and as of the Closing Date and any Additional Closing Date; and the statements of the Company and its officers

made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date and any Additional

Closing Date.

(c)

No Material Adverse Change. No event or condition of a type described in Section 3(f) hereof shall have occurred or shall

exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and

the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the judgment of the Representative makes it

impracticable or inadvisable to proceed with the public offering, sale or delivery of the Securities on the Closing Date and any Additional

Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.

(d)

Officer’s Certificate. The Representative shall have received on and as of the Closing Date and any Additional Closing

Date, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer

of the Company who is reasonably satisfactory to the Representative, on behalf of the Company and not in their individual capacities (i)

confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and,

to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(d) hereof are true and correct, (ii) confirming

that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied

in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior

to the Closing Date or Additional Closing Date, as the case may be, and (iii) to the effect set forth in paragraphs (a), (b) and (c) above.

(e)

Comfort Letters. On the date of this Agreement and on the Closing Date and any Additional Closing Date, MNP LLP shall have

furnished to the Representative, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed

to the Representative, in form and substance reasonably satisfactory to the Representative, containing statements and information of the

type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements

and certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure

Package and the Prospectus; provided, that the letter delivered on the Closing Date and any Additional Closing Date, shall use

a “cut-off” date reasonably acceptable to the Representative.

(f)

Opinion and Negative Assurance Letter of United States Counsel for the Company. Lowenstein Sandler LLP, United States counsel

for the Company, shall have furnished to the Representative, at the request of the Company, their written opinion and negative assurance

letter, dated the Closing Date or the Additional Closing Date, as applicable, and addressed to the Representative, in form and substance

reasonably satisfactory to the Representative.

(g)

Opinion of Canadian Local Counsel for the Company. Fasken Martineau DuMoulin, LLP, Canadian local counsel for the Company,

shall have furnished to the Representative, at the request of the Company, their written opinion, dated the Closing Date or the Additional

Closing Date, as applicable, and addressed to the Representative, in form and substance reasonably satisfactory to the Representative.

(h)

Opinion of Intellectual Property Counsel for the Company. Fenwick & West LLP, intellectual property counsel for the

Company, shall have furnished to the Representative, at the request of the Company, their written opinion, dated the Closing Date or the

Additional Closing Date, as the case may be, and addressed to the Representative, in form and substance reasonably satisfactory to the

Representative.

(i)

Opinion and Negative Assurance Letter of Counsel for the Underwriters. The Representative shall have received on and as

of the Closing Date and any Additional Closing Date, for itself and on behalf of the several Underwriters, an opinion and negative assurance

letter of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., counsel for the Underwriters, with respect to such matters as the Representative

may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them

to pass upon such matters.

(j)

No Legal Impediment to Issuance and Sale. No action shall have been taken and no statute, rule, regulation or order shall

have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing

Date or any Additional Closing Date, prevent the issuance or sale of the Securities; and no injunction or order of any federal, state

or foreign court shall have been issued that would, as of the Closing Date or any Additional Closing Date, prevent the issuance or sale

of the Securities.

(k)

Good Standing. The Representative shall have received on and as of the Closing Date and any Additional Closing Date satisfactory

evidence of the good standing of the Company in its jurisdiction of organization and its good standing as foreign entities in such other

jurisdictions as the Representative may reasonably request, in each case in writing or any standard form of telecommunication from the

appropriate governmental authorities of such jurisdiction.

(l)

Exchange Listing. The Securities to be delivered on the Closing Date and the Additional Closing Date, as applicable, shall

have been approved for listing on the Nasdaq Capital Market, subject to official notice of issuance.

(m)

Lock-up Agreements. The Lock-up Agreements, each substantially in the form of Exhibit C hereto, between you and all

of the officers and directors of the Company relating to sales and certain other dispositions of Common Shares or certain other securities,

delivered to you on or before the date hereof, shall be in full force and effect on the Closing Date and any Additional Closing Date.

(n)

Certificate of Chief Financial Officer. The Representative shall have received on the date of this Agreement and as of the

Closing Date and any Additional Closing Date, a certificate of the chief financial officer in form and substance reasonably satisfactory

to the Representative and counsel for the Underwriters, with respect to certain financial information contained in the Registration Statement,

the Pricing Disclosure Package, and the Prospectus.

(o)

Form of Pre-Funded Warrants. On or prior to the Closing Date, the Pre-Funded Warrants shall be delivered to those persons

and entities as directed by the Representative in form and substance as set forth on Exhibit A hereto dated as of such date.

(p)

Form of Common Warrants. On or prior to the Closing Date, the Common Warrants shall be delivered to those persons and entities

as directed by the Representative in form and substance as set forth on Exhibit B hereto dated as of such date.

(q)

Additional Documents. On or prior to the Closing Date and any Additional Closing Date, the Company shall have furnished

to the Representative such further certificates and documents as the Representative may reasonably request.

All opinions, letters, certificates and evidence mentioned

above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance

reasonably satisfactory to counsel for the Underwriters.

Indemnification and Contribution.

(a)

Indemnification of the Underwriters. The Company agrees to indemnify and hold harmless each Underwriter, its affiliates,

directors and officers and each person, if any, who controls such Underwriter within the meaning of Section 15 of the Securities Act or

Section 20 of the Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable

and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such

fees and expenses are incurred) that arise out of, or are based upon, (i) any untrue statement or alleged untrue statement of a material

fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to

be stated therein or necessary in order to make the statements therein, not misleading, or (ii) any untrue statement or alleged untrue

statement of a material fact contained in the Prospectus (or any amendment or supplement thereto), any preliminary prospectus, any Issuer

Free Writing Prospectus, any “issuer information” filed or required to be filed pursuant to Rule 433(d) under the Securities

Act, any road show as defined in Rule 433(h) under the Securities Act (a “road show”) or any Pricing Disclosure Package

(including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state

therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not

misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement

or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including any information

deemed to be a part thereof pursuant to Rule 430B, the Pricing Disclosure Package or the Prospectus (or any amendment or supplement thereto)

in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by the Representative

on behalf of such Underwriter expressly for use therein, it being understood and agreed that the only such information furnished by the

Representative consists of the information described as such in subsection (b) below.

(b)

Indemnification of the Company. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company,

its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning

of Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) above,

but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission

or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished

to the Company in writing by the Representative on behalf of such Underwriter expressly for use in the Registration Statement, the Prospectus

(or any amendment or supplement thereto), any preliminary prospectus, any Issuer Free Writing Prospectus, any road show or any Pricing

Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon

that the only such information furnished by the Representative on behalf of the Underwriters consists of the following information in

the Prospectus furnished on behalf of the Underwriters: the information contained in the first and second sentences in the fifth paragraph

under the caption “Underwriting.”

(c)

Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or

demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs

of this Section 7, such person (the “Indemnified Person”) shall promptly notify the person against whom such indemnification

may be sought (the “Indemnifying Person”) in writing; provided that the

failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under the preceding paragraphs

of this Section 7 except to the extent that it has been materially prejudiced (through the forfeiture

of substantive rights or defenses) by such failure; and provided, further, that the failure to notify the Indemnifying Person

shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs

of this Section 7. If any such proceeding shall be brought or asserted against an Indemnified Person

and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory

to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent

the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate

in such proceeding and shall pay the reasonable and documented fees and expenses in such proceeding, and shall pay the reasonable and

documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall

have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Person

unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person

has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii) the Indemnified Person

shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available

to the Indemnifying Person; or (iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying

Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or potential

differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding

or related proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any

local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any

such separate firm for the Underwriters, their affiliates, directors and officers and any control persons of the Underwriters shall be

designated in writing by the Representative, and any such separate firm for the Company, its directors, its officers who signed the Registration

Statement and any control persons of the Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable

for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees

to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement.

Notwithstanding the foregoing

sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees

and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding

effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person

of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior

to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement

of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could

have been sought hereunder by such Indemnified Person, unless such settlement (x) includes an unconditional release of such Indemnified

Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter

of such proceeding and (y) does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf

of any Indemnified Person.

(d)

Contribution. If the indemnification provided for in paragraphs (a) and (b) above is unavailable to an Indemnified Person

or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such

paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified

Person as a result of such losses, claims, damages or liabilities (i) in such proportion as is appropriate to reflect the relative benefits

received by the Company, on the one hand, and the Underwriters on the other, from the public offering of the Securities or (ii) if the

allocation provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative

benefits referred to in clause (i) but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in

connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant

equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be

deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale

of the Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case

as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of the Securities. The relative fault of

the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the

untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information

supplied by the Company or by the Underwriters and the parties’ relative intent, knowledge, access to information and opportunity

to correct or prevent such statement or omission.

(e)

Limitation on Liability. The Company and the Underwriters agree that it would not be just and equitable if contribution

pursuant to paragraph (d) above were determined by pro rata allocation (even if the Underwriters were treated as one entity for

such purpose) or by any other method of allocation that does not take account of the equitable considerations referred to in paragraph

(d) above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to

in paragraph (d) above shall be deemed to include, subject to the limitations set forth above, any reasonable and documented legal or

other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs

(d) and (e), no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting discounts

and commissions received by such Underwriter with respect to the public offering of the Securities exceeds the amount of any damages that

such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission.

The Underwriters’ obligations to contribute pursuant to this Section 7 are several, and not joint, in proportion to their respective

underwriting commitments as set forth opposite their respective names in Schedule 1 hereto. No person guilty of fraudulent misrepresentation

(within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such

fraudulent misrepresentation.

(f)

Non-Exclusive Remedies. The remedies provided for in this Section 7 are not exclusive and shall not limit any rights or

remedies which may otherwise be available to any Indemnified Person at law or in equity.

Effectiveness of Agreement. This Agreement shall become effective as of the date first written above.

Default of One or More of the Several Underwriters. If, on the Closing Date or any Additional Closing Date, any one or more

of the several Underwriters shall fail or refuse to purchase Securities that it or they have agreed to purchase hereunder on such date,

and the aggregate number of Securities which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does

not exceed 10% of the aggregate number of the Securities to be purchased on such date, the Representative may make arrangements satisfactory

to the Company for the purchase of such Securities by other persons, including any of the Underwriters, but if no such arrangements are

made by such date, the other Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Underwritten

Shares, the Pre-Funded Warrants, and the Underwritten Common Warrants set forth opposite their respective names on Schedule 1 bears

to the aggregate number of Underwritten Shares, the Pre-Funded Warrants, and the Underwritten Common Warrants set forth opposite the names

of all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representative with the consent of the

non-defaulting Underwriters, to purchase the Securities which such defaulting Underwriter or Underwriters agreed but failed or refused

to purchase on such date. If, on the Closing Date or any Additional Closing Date, any one or more of the Underwriters shall fail or refuse

to purchase Securities and the aggregate number of Securities with respect to which such default occurs exceeds 10% of the aggregate number

of Securities to be purchased on such date, and arrangements satisfactory to the Representative and the Company for the purchase of such

Securities are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other

party except that the provisions of Section 7 and Section 10 shall at all times be effective and shall survive such termination. In any

such case, either the Representative or the Company shall have the right to postpone the Closing Date or the applicable Additional Closing

Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement

and the Prospectus or any other documents or arrangements may be effected. As used in this Agreement, the term “Underwriter”

shall be deemed to include any person substituted for a defaulting Underwriter under this Section. Any action taken under this Section

shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement.

10.

Termination. This Agreement may be terminated in the absolute discretion of the Representative, by notice to the Company,

if after the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares and accompanying

Option Common Warrants, on or prior to the Additional Closing Date: (i) any domestic or international event or act or occurrence has materially

disrupted, or in the opinion of the Representative will in the immediate future materially disrupt, the market for the Company’s

securities or securities in general; (ii) trading generally shall have been suspended or materially limited on or by any of the New York

Stock Exchange or The Nasdaq Stock Market LLC; (iii) trading of any securities issued or guaranteed by the Company shall have been suspended

on any exchange or in any over-the-counter market; (iv) a general moratorium on commercial banking activities shall have been declared

by federal or New York State authorities; (v) (A) there shall have occurred any outbreak or escalation of hostilities or acts of terrorism

involving the United States or there is a declaration of a national emergency or war by the United States or (B) there shall have been

any other calamity or crisis or any change in political, financial or economic conditions if the effect of any such event in (A) or (B),

in the judgment of the Representative, makes it impracticable or inadvisable to proceed with the public offering, sale or delivery of

the Securities on the Closing Date, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and

the Prospectus; or (vi) any of the events described in Section 3(f) shall have occurred or any Underwriter shall decline to purchase the

Securities for any reason permitted under this Agreement.

11.

Payment of Expenses; Solicitation Fee of the Exercise of the Common Warrants.

(a)

Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will

pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation,

(i) the costs incident to the authorization, issuance, sale, preparation and delivery of the

Securities and any stamp or transfer taxes payable in that connection; (ii) the costs incident to the preparation, printing

and filing under the Securities Act of the Registration Statement, any preliminary prospectus, any Issuer Free Writing Prospectus, any

Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and

the distribution thereof; (iii) the fees and expenses of the Company’s counsel and independent accountants; (iv) the fees and

expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities

under the state or foreign securities or blue sky laws of such jurisdictions as the Representative may designate and

the preparation, printing and distribution of a Blue Sky Memorandum and any “Canadian wrapper” (including the related

documented fees and expenses of counsel for the Underwriters in an amount not to exceed $5,000 (excluding filing fees)); (v)

the cost of preparing share certificates; (vi) the costs and charges of any transfer agent, warrant agent, and any registrar; (vii)

all expenses and application fees incurred in connection with any filing with, and clearance of the public offering

by, FINRA, provided that the aggregate amount payable by the Company pursuant to clauses (iv) and (vii) shall not exceed

$20,000 (excluding filing fees); and (viii) all expenses incurred by the Company in connection with any “road show” presentation

to potential investors (provided, however, that the Underwriters and the Company shall each pay 50% of the cost of chartering

any aircraft to be used in connection with the road show by both the Company and the Underwriters, and all lodging, commercial airfare

and individual expenses of the Underwriters shall be the responsibility of the Underwriters); (ix) all

expenses and application fees related to the listing of the Securities on the Nasdaq Capital Market and (x) all reasonable fees

and expenses incurred by the Underwriters in connection with the issuance of the Securities such as fees and disbursements of counsel

and out-of-pocket expenses related to the issuance of the Securities; provided that the expense reimbursement payable to the Underwriters

under this paragraph shall not exceed $150,000 in aggregate without the Company’s consent and shall be invoiced in reasonable detail.

(b)

If (i) this Agreement is terminated pursuant to Section 10, (ii) the Company for any reason fails to tender the Securities for

delivery to the Underwriters or (iii) any Underwriter declines to purchase the Securities for any reason permitted under this Agreement,

the Company agrees to reimburse the Representative and the other Underwriters (or such Underwriters as have terminated this Agreement

with respect to themselves), severally, for all out-of-pocket costs and expenses (including the fees and expenses of their counsel) reasonably

incurred by the Representative and the Underwriters in connection with this Agreement and the public offering contemplated hereby; provided,

however, that no additional amounts beyond what has been reimbursed pursuant to the foregoing will be owed to the Underwriters

other than under Section 7 hereof. For the avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs,

fees or expenses incurred by an Underwriter if it defaults on its obligations to purchase the Securities.

(c)

The Company hereby engages the Representative as its exclusive agent for the solicitation of the exercise of the Common Warrants.

The Company will (i) assist the Representative with respect to the solicitation, if requested by the Representative, and (ii) provide

the Representative lists of the record and, to the extent known, beneficial owners of the Common Warrants. For each Common Warrant exercised,

the Company will pay the Underwriters a solicitation fee (the “Solicitation Fee”) of six percent (6%) of the exercise

price of the Common Warrants. The Company shall provide the Representative with written notice of each exercise of Common Warrants within

24 hours of the applicable exercise date of such Common Warrants. Any such Solicitation Fee shall be paid to the Underwriters not less

than two (2) business days after the exercise date giving rise to such Solicitation Fee and shall be paid by wire transfer of immediately

available funds to an account previously specified by the Representative. The Company agrees to disclose the arrangement to pay the Solicitation

Fee to the Representative in the Pricing Disclosure Package and the Prospectus. Notwithstanding the foregoing, as required by FINRA Rule

5110(g)(10), no Solicitation Fee shall be payable to the Representative hereunder in respect of the exercise of a Common Warrant if: (i)

the market price of the underlying Common Shares is lower than the exercise price of the Common Warrant at the time of exercise; (ii)

the Common Warrant is held in a discretionary account of the Representative at the time of exercise, unless prior specific written approval

for the exercise is received from the holder; (iii) the arrangement to pay the Solicitation Fee is not disclosed in the Pricing Disclosure

Package and Prospectus or in any prospectus provided to the holder of the Common Warrant at the time of exercise; or (iv) the Common Warrant

is exercised in an unsolicited transaction.

12.

Persons Entitled to Benefit of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto

and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each

Underwriter referred to in Section 7 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any

legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Securities

from any Underwriter shall be deemed to be a successor merely by reason of such purchase.

13.

Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company

and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement

or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force

and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters

or the directors, officers, controlling persons or affiliates referred to in Section 7 hereof.

14.

Certain Defined Terms. For purposes of this Agreement, (a) except where otherwise expressly provided, the term “affiliate”

has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day

on which banks are permitted or required to be closed in New York City; (c) the term “subsidiary” has the meaning set forth

in Rule 405 under the Securities Act; and (d) the term “significant subsidiary” has the meaning set forth in Rule 1-02 of

Regulation S-X under the Exchange Act. In the event that the Company has only one subsidiary, then all references herein to “subsidiaries”

of the Company shall be deemed to refer to such single subsidiary, mutatis mutandis.

15.

Compliance with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56

(signed into law October 26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective

clients, including the Company, which information may include the name and address of their respective clients, as well as other information

that will allow the Underwriters to properly identify their respective clients.

16.

Miscellaneous.

(a)

Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given

if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representative

at Guggenheim Securities, LLC, 330 Madison Avenue, New York, NY 10017, Attention: General Counsel, with a copy to Mintz, Levin, Cohn,

Ferris, Glovsky and Popeo, P.C., One Financial Center, Boston, MA 02111, Attention: William C. Hicks, John T. Rudy and Alok A. Choksi;

notices to the Company shall be given to it at Edesa Biotech, Inc., 100 Spy Court, Markham, ON, Canada L3R 5H6, Telephone:(289) 800-9600,

Attention: Chief Financial Officer, with a copy to Lowenstein Sandler LLP, 1251 Avenue of the Americas, New York, NY 10020, Attention:

Steven M. Skolnick. Any party hereto may change the address for receipt of communications by giving written notice to the others.

(b)

Governing Law. This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be

governed by and construed in accordance with the laws of the State of New York applicable to agreements made and to be performed in such

state.

(c)

Waiver of Jury Trial. Each of the parties hereto hereby irrevocably waives, to the fullest extent permitted by applicable

law, any and all right to trial by jury in any suit or legal proceeding arising out of or relating to this Agreement or the transactions

contemplated hereby.

(d)

Counterparts. This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form

of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts

may be delivered via facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform

Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission

method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

(e)

Amendments or Waivers. No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure

therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto.

(f)

Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect

the meaning or interpretation of, this Agreement.

(g)

Integration. This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company

and the Underwriters with respect to the subject matter hereof.

(h)

Recognition of the U.S. Special Resolution Regimes.

(i) In the event that any Underwriter is

a Covered Entity and becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer from such Underwriter of this

Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective

under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United

States or a state of the United States.

(ii) In the event that any Underwriter is

a Covered Entity or a BHC Act Affiliate of the Underwriter and becomes subject to a proceeding under a U.S. Special Resolution Regime,

Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent

than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the

United States or a state of the United States.

As used in this Section 16(h):

“BHC Act Affiliate” has the meaning

assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12 U.S.C. § 1841(k).

“Covered Entity” means any of the

following:

(i) a “covered entity” as that term

is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);

(ii) a “covered bank” as that term

is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or

(iii) a “covered FSI” as that term

is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b).

“Default Right” has the meaning

assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable.

“U.S. Special Resolution Regime”

means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall

Street Reform and Consumer Protection Act and the regulations promulgated thereunder.

[Signature Page Follows]

If the foregoing is in accordance with your understanding,

please indicate your acceptance of this Agreement by signing in the space provided below.

Very truly yours,

EDESA BIOTECH, INC.

By:

/s/ Pardeep Nijhawan

Name: Pardeep Nijhawan

Title: Chief Executive Officer

[Signature Page to Underwriting Agreement]

The foregoing Underwriting Agreement is hereby confirmed

and accepted by the Representative as of the date first above written.

GUGGENHEIM SECURITIES, LLC

Acting individually and as Representative

of the several Underwriters named in the attached Schedule 1.

By:

/s/ Geoffrey Goodman

Name: Geoffrey Goodman

Title: Senior Managing Director

[Signature Page to Underwriting Agreement]

Schedule 1

Underwriters

Number of

Underwritten

Number of

Pre-Funded

Warrants

Number of

Underwritten

Common

Warrants

Guggenheim Securities, LLC

3,870,500

675,000

4,545,500

Total

3,870,500

675,000

4,545,500

Annex A

a. Free Writing Prospectus

None.

b. Pricing Information Provided Orally by Underwriters

Combined Public Offering Price per Underwritten

Common Share and Accompanying Underwritten Common Warrant: $5.50

Combined Public Offering Price per Pre-Funded

Warrant and Accompanying Underwritten Common Warrant: $5.4999

Number of Underwritten Shares: 3,870,500

Number of Underwritten Common Warrants accompanying

the Underwritten Shares: 3,870,500

Number of Pre-Funded Warrants: 675,000

Number of Underwritten Common Warrants accompanying

the Pre-Funded Warrants: 675,000

Number of Option Shares: 681,825

Number of Option Common Warrants accompanying the Option

Shares: 681,825

Annex B

Pricing Term Sheet

None.

Exhibit A

Form of Pre-Funded Warrant

[See attached]

Exhibit B

Form of Common Warrant

[See attached]

Exhibit C

Form of Lock-up Agreement

[See attached]

Form of Lock-up Agreement

________, 2026

Guggenheim Securities, LLC,

as Representative of the Underwriters

c/o Guggenheim Securities, LLC

330 Madison Avenue

New York, NY 10017

Re: Edesa Biotech, Inc.

Ladies and Gentlemen:

The undersigned, a shareholder of Edesa Biotech, Inc.,

a company organized under the laws of British Columbia, Canada (the “Company”), understands that you, as representative

of the underwriters (the “Representative”), propose to enter into an Underwriting Agreement (the “Underwriting

Agreement”) with the Company, providing for a public offering (the “Offering”) by the Company, of its common

shares, without par value (the “Common Shares”) and/or pre-funded warrants to purchase Common Shares (together with

the Common Shares, the “Securities”). Capitalized terms used herein and not otherwise defined shall have the meanings

set forth in the Underwriting Agreement. To the extent there are no additional underwriters listed on Schedule 1 to the Underwriting

Agreement, the term “Representative” as used herein shall mean you, as Underwriter, and the term “Underwriters”

shall mean either the singular or the plural, as the context requires.

Annex A sets forth definitions for capitalized terms

used in this Letter Agreement (as defined below) that are not defined in the body of this Letter Agreement. Those definitions are part

of this Letter Agreement.

In consideration of the Underwriters’ agreement

to purchase and make the Offering of the Securities, and for other good and valuable consideration receipt of which is hereby acknowledged,

the undersigned hereby agrees that, without the prior written consent of Guggenheim Securities, LLC, the undersigned will not, during

the period beginning on the date of this letter agreement (this “Letter Agreement”) and ending 90 days after the date

of the final prospectus supplement relating to the Offering (the “Prospectus”) (such period, the “Restricted

Period”), (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract

to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any Securities or

any securities convertible into or exercisable or exchangeable for Securities (including without limitation, Securities or such other

securities which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations of the Securities

and Exchange Commission and securities which may be issued upon exercise of a share option or warrant), (2) enter into any swap or other

agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Securities or such other securities,

whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Securities or such other securities,

in cash or otherwise, (3) make any demand for or exercise any right with respect to the registration of any Securities or any security

convertible into or exercisable or exchangeable for Securities (and, for the avoidance of doubt, the undersigned hereby waives any and

all notice requirements and rights with respect to the registration of any securities pursuant to any agreement, instrument, understanding

or otherwise, including any shareholders or registration rights agreement or similar agreement, to which the undersigned is a party or

under which the undersigned is entitled to any right or benefit), or (4) publicly disclose the intention to do any of the foregoing described

in clauses (1), (2) and (3) above, in each case other than:

(A) transfers of Securities or any security convertible into or exercisable or exchangeable for Securities as

a bona fide gift or gifts or for bona fide estate planning purposes including, without limitation, transfers to charitable

organizations;

(B) transfers or distributions of Securities or any security convertible into or exercisable or exchangeable

for Securities to (i) limited partners, members, shareholders or holders of similar equity interests in the undersigned or (ii) to another

corporation, partnership, limited liability company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated

under the Securities Act) of the undersigned, including without limitation any general partner, limited partner, managing member, manager,

member, employee, officer or director of such entity or any trust for the benefit of any of the foregoing or any affiliate of the foregoing,

or to any investment fund or other entity controlled or managed by the undersigned or affiliates of the undersigned;

after the completion of the Offering; provided, that no public disclosure or filing under Section 16(a) of the Exchange Act shall

be voluntarily made during the Restricted Period in connection with subsequent sales of Securities or other securities acquired in the

Offering or such open market transactions during the Restricted Period, and any required filing under Section 16(a) of the Exchange Act

in connection with any such subsequent sale shall indicate in the footnotes thereto that the filing relates to the circumstances described

in this clause;

(D) (i) transfers or dispositions of Securities or any security convertible into or exercisable or exchangeable

for Securities by will or intestacy or (ii) to any Family Member or to a trust whose beneficiaries consist exclusively of one or more

of the undersigned and/or a Family Member;

(E) transfers of Securities or any security convertible into or exercisable or exchangeable for Securities pursuant

to a domestic order, negotiated divorce settlement or other court order; provided, that any required filing under Section 16 of

the Exchange Act shall indicate in the footnotes thereto that the filing relates to the circumstances described in this clause and no

other public announcement shall be made voluntarily in connection with such transfer or disposition during the Restricted Period; provided

further, that in the case of a negotiated divorce settlement, such transferee agrees to be bound by the restrictions on transfer set

forth herein;

(F) the exercise of a warrant or the conversion of preferred shares, or the exercise of a share option, or the

vesting or settlement of restricted share units or other equity awards, in each case granted under an equity incentive plan described

in the Prospectus for Securities, including any transfer of Securities to the Company (i) in connection with the net or cashless exercise

of such warrant or share option, including for the payment of the exercise price thereof, or (ii) withholding of Securities by the Company,

in each case solely to satisfy tax withholding obligations of the undersigned arising from such exercise, conversion, vesting or settlement;

provided, that the underlying Securities received by the undersigned (other than any Securities withheld or transferred to the

Company as described above) shall continue to be subject to the restrictions on transfer set forth in this Letter Agreement; provided

further, that no filing under Section 16(a) of the Exchange Act or other public filing, report or announcement shall be voluntarily

made during the Restricted Period, and any public report or filing under Section 16 of the Exchange Act shall clearly indicate in the

footnotes thereto that (i) the filing relates to such exercise, conversion, vesting or settlement and, if applicable, the related withholding

or transfer, (ii) no Securities were sold by the reporting person and (iii) Securities so received (other than any withheld or transferred

as described above) are subject to this Letter Agreement with the Representative of the Offering;

(G) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of Securities;

provided, that (i) such plan does not provide for the transfer of Securities during the Restricted Period and (ii) to the extent

a public announcement or filing under the Exchange Act, if any, is required by or on behalf of the undersigned or the Company regarding

the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of Securities may

be made under such plan during the Restricted Period;

(H) pursuant to a bona fide third party tender offer for all outstanding Securities of the Company, merger,

consolidation or other similar transaction approved by the Company’s Board of Directors and made to all holders of the Company’s

securities involving a Change of Control of the Company (including, without limitation, the entering into of any lock-up, voting or similar

agreement pursuant to which the undersigned may agree to transfer, sell, tender or otherwise dispose of Securities or other such securities

in connection with such transaction, or vote any Securities or other such securities in favor of any such transaction); provided,

that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by the

undersigned shall remain subject to the provisions of this Letter Agreement;

(I) transfers or forfeitures of Securities to the Company, including without limitation upon the vesting or forfeiture

of restricted share units, restricted shares, options or other equity awards, in connection with the termination of the undersigned’s

employment or other service relationship with the Company, in each case pursuant to contractual arrangements in effect prior to the date

of this Letter Agreement or approved by the Company’s Board of Directors; and

(J) transfers of Securities or any security convertible into or exercisable or exchangeable for Securities as

bona fide collateral or security to a financial institution pursuant to a bona fide loan, credit facility or other financing arrangement,

and any transfer or disposition of such Securities upon a bona fide foreclosure or default under such arrangement; provided, that

no filing under Section 16(a) of the Exchange Act or other public announcement or filing shall be voluntarily made in connection with

such pledge during the Restricted Period, and any filing under Section 16(a) of the Exchange Act reporting a reduction in beneficial ownership

in connection with such pledge or any foreclosure thereon shall clearly indicate in the footnotes thereto the nature of such transfer;

provided, that in the case of any transfer or distribution pursuant

to clause (A), (B) or (D), each donee or distributee shall execute and deliver to the Representative a lock-up letter in the form of this

Letter Agreement; provided further, that in the case of any transfer or distribution pursuant to clause (A), (B) or (D), no filing

by any party (donor, donee, transferor or transferee) under the Exchange Act or other public announcement shall be required or shall be

made voluntarily in connection with such transfer or distribution, other than (x) a filing on a Form 5 made after the expiration of the

Restricted Period referred to above, or (y) in the case of a transfer or disposition pursuant to clause (A) or (B) above, any Form 4 or

Form 5 required to be filed under the Exchange Act if the undersigned is subject to Section 16 reporting with respect to the Company under

the Exchange Act, indicating by footnote disclosure or otherwise the nature of the transfer or the disposition; provided further,

in the case of clauses (B) and (D), any such transfer shall not involve a disposition for value.

In furtherance of the foregoing, the Company, and any

duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to

make any transfer of securities if such transfer would constitute a violation or breach of this Letter Agreement.

The undersigned hereby represents and warrants that

the undersigned has full power and authority to enter into this Letter Agreement. All authority herein conferred or agreed to be conferred

and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned.

The undersigned acknowledges and agrees that the Underwriters

have not provided any recommendation or investment advice nor have the Underwriters solicited any action from the undersigned with respect

to the Offering of the Securities and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors

to the extent deemed appropriate. The undersigned further acknowledges and agrees that, although the Underwriters may be required or choose

to provide certain Regulation Best Interest and Form CRS disclosures in connection with the Offering, the Representative and the other

Underwriters are not making a recommendation to enter into this Letter Agreement, and nothing set forth in such disclosures is intended

to suggest that the Representative or any Underwriter is making such a recommendation.

The undersigned understands that, if (i) either the

Company notifies or the Representative notifies the other in writing prior to the execution of the Underwriting Agreement that it does

not intend to proceed with the Offering, (ii) the Underwriting Agreement does not become effective by the end of the Restricted Period,

or (iii) if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated

prior to payment for and delivery of the Securities to be sold thereunder, the undersigned shall be released from all obligations under

this Letter Agreement. The undersigned understands that the Representative is entering into the Underwriting Agreement and proceeding

with the Offering in reliance upon this Letter Agreement.

This Letter Agreement and any claim, controversy or

dispute arising under or related to this Letter Agreement shall be governed by and construed in accordance with the laws of the State

of New York, without regard to the conflict of laws principles thereof.

[Signature Page Follows]

Very truly yours,

________________________________________

Name of Security Holder (Print

exact name)

By: _______________________________________

(Signature)

If not signing in an individual capacity:

________________________________________

Name of Authorized Signatory (Print)

________________________________________

Title of Authorized Signatory (Print)

(indicate capacity of person signing if signing as custodian, trustee,

or on behalf of an entity)

Annex A

Certain Defined Terms Used in this Lock-up Agreement

For purposes of this Letter Agreement to which this

Annex A is attached and of which it is made a part:

“Change of Control” means the consummation

of any bona fide third party tender offer, merger, consolidation or other similar transaction, the result of which is that any

“person” (as defined in Section 13(d)(3) of the Exchange Act), or group of persons, other than the Company or its subsidiaries,

becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 of the Exchange Act) of at least 50% of the total voting power of the

voting share capital of the Company.

“Exchange Act” shall mean the Securities

Exchange Act of 1934, as amended.

“Family Member” shall mean the spouse

of the undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned’s spouse, in

each case living in the undersigned’s household or whose principal residence is the undersigned’s household (regardless of

whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military

service, temporary internship or employment or otherwise).

“Immediate family member” as used

above shall have the meaning set forth in Rule 16a-1(e) under the Exchange Act.

“Securities Act” shall mean the

Securities Act of 1933, as amended.

Capitalized terms not defined in this Annex A shall

have the meanings given to them in the body of this Letter Agreement.

EX-4.1 — EXHIBIT 4.1

EX-4.1

Filename: exh_41.htm · Sequence: 3

Exhibit 4.1

COMMON SHARE PURCHASE WARRANT

EDESA BIOTECH INC.

Warrant Shares: [__]

Issuance Date: August 21, 2026

THIS WARRANT TO PURCHASE COMMON SHARES (the “Warrant”)

certifies that, for value received, [______] or its assigns (the “Holder”) is entitled, upon the terms and subject

to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial

Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on the earlier of (i) February 21, 2028 and (ii) the 30th

day following the date of the Milestone Event, provided that, if such date falls on a day other than a Trading Day, the next day (such

earlier date, the “Termination Date”) but not thereafter, to subscribe for and purchase from Edesa Biotech Inc., a

British Columbia corporation (the “Company”), up to [__] common shares, no par value, of the Company (the “Common

Shares”) (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Common Share

under this Warrant shall be equal to the Exercise Price, as defined in Section 1(b). As used herein, “Milestone Event”

means the public announcement via press release or the filing of a Current Report on Form 8-K of Phase 2 vitiligo topline data for EB06.

The Company shall provide written notice to the Holder within five (5) Trading Days of the occurrence of the Milestone Event.

This Warrant has been issued pursuant to the terms of the Underwriting Agreement, dated August 19, 2026, between the Company and

Guggenheim Securities, LLC, as the representative of the several underwriters named therein.

Section 1. Exercise.

(a) Exercise of Warrant. Exercise of the purchase rights represented

by this Warrant may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination

Date by delivery to the Company of a duly executed facsimile copy or PDF copy submitted by e-mail (or e-mail attachment) of the Notice

of Exercise in the form annexed hereto (the “Notice of Exercise”). Within the earlier of (i) one (1) Trading Day (as

defined below) and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 1(d)(i) herein) following

the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable

Notice of Exercise by wire transfer or cashier’s check drawn on a United States bank unless the cashless exercise procedure specified

in Section 1(c) below is specified in the applicable Notice of Exercise. No ink-original Notice of Exercise shall be required, nor shall

any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. The Company shall have no

obligation to inquire with respect to or otherwise confirm the authenticity of the signature(s) contained on any Notice of Exercise nor

the authority of the person so executing such Notice of Exercise. Notwithstanding anything herein to the contrary, the Holder shall not

be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder

and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within

three (3) Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant

resulting in purchases of a portion of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding

number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and

the Company shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver

any objection to any Notice of Exercise within one (1) Trading Day of its receipt of such notice. The Holder and any assignee, by acceptance

of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the

Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount

stated on the face hereof.

(b) Exercise Price. The exercise price per Common Share under this

Warrant shall be $7.50, subject to adjustment hereunder (the “Exercise Price”).

there is no effective registration statement registering, or the prospectus contained therein is not available for, or an exemption from

registration is not available for, the issuance of the Warrant Shares, then this Warrant may also be exercised, in whole or in part, at

such time by means of a “cashless exercise” in which the Holder shall be entitled to receive a number of Warrant Shares equal

to the quotient obtained by dividing [(A-B) (X)] by (A), where:

(A)

as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 1(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 1(a) hereof on a Trading Day prior to the opening of “regular trading hours” (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Shares on the principal Trading Market as reported by Bloomberg L.P. (“Bloomberg”) as of the time of the Holder’s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during “regular trading hours” on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of “regular trading hours” on a Trading Day) pursuant to Section 1(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 1(a) hereof after the close of “regular trading hours” on such Trading Day;

(B)

the Exercise Price of this Warrant, as adjusted hereunder; and

(X)

the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.

If Warrant Shares are issued in such a cashless exercise, the parties acknowledge

and agree that in accordance with Section 3(a)(9) of the Securities Act, the Warrant Shares shall take on the characteristics of the Warrants

being exercised, and the holding period of the Warrant Shares being issued may be tacked by such Holder to the holding period of such

Holder of this Warrant. The Company agrees not to take any position contrary to this paragraph.

“Bid Price” means, for any date, the price determined

by the first of the following clauses that applies: (a) if the Common Shares are then listed or quoted on a Trading Market, the bid price

of the Common Shares for the time in question (or the nearest preceding date) on the Trading Market on which the Common Shares are then

listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)),

(b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Shares for such date (or the nearest preceding

date) on OTCQB or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or OTCQX and if prices

for the Common Shares are then reported on The Pink Open Market (or a similar organization or agency succeeding to its functions of reporting

prices), the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market value of a Common Share as

determined by the Board of Directors of the Company in good faith.

“Trading Day” means a day on which the principal Trading

Market is open for trading.

“Trading Market” means any of the following markets

or exchanges on which the Common Shares are listed or quoted for trading on the date in question: the NYSE American, the Nasdaq Capital

Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange, the OTCQB or the OTCQX (or any successors

to any of the foregoing).

“VWAP” means, for any date, the price determined by

the first of the following clauses that applies: (a) if the Common Shares are then listed or quoted on a Trading Market, the daily volume

weighted average price of the Common Shares for such date (or the nearest preceding date) on the Trading Market on which the Common Shares

are then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:00 p.m. (New York

City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Shares for such date (or the

nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Shares are not then listed or quoted for trading on OTCQB or

OTCQX and if prices for the Common Shares are then reported in The Pink Open Market (or a similar organization or agency succeeding to

its functions of reporting prices), the most recent bid price per Common Share so reported, or (d) in all other cases, the fair market

value of a Common Share as determined by the Board of Directors of the Company in good faith.

(d) Mechanics of Exercise.

(i) Delivery of Warrant Shares Upon Exercise. The Company shall

cause the Warrant Shares purchased hereunder to be delivered by the Transfer Agent to the Holder by crediting the account of the Holder’s

or its designee’s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (“DWAC”)

if the Company is then a participant in such system and either (A) there is an effective registration statement permitting the issuance

of the Warrant Shares to the Holder or resale of the Warrant Shares (and a concurrent resale is being made) by the Holder or (B) the Warrant

Shares are eligible for resale by the Holder without volume or manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise

of the Warrants), in each case, subject to the delivery by the Holder to the Company and its counsel and the Transfer Agent of customary

representation letters and such other documents as such person may request, and otherwise by physical delivery of a certificate or a book-entry

notation, registered in the Company’s share register in the name of the Holder or its designee, for the number of Warrant Shares

to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date

that is the earliest of (i) one (1) Trading Day after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day

after delivery of the aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement

Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery Date”);

provided, that if any day within the Standard Settlement Period is a day on which banks in British Columbia, Canada are not open

for business, the Standard Settlement Period shall be extended by one Trading Day for each such day. Upon delivery of the Notice of Exercise

to the Company, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect

to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate

Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) one (1) Trading Day and (ii) the

number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise to the Company. If the Company

fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the

Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such

exercise (based on the VWAP of the Common Shares on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to

$20 per Trading Day on the fifth Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery

Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is

a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, “Standard Settlement

Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary Trading

Market with respect to the Common Shares as in effect on the date of delivery of the Notice of Exercise to the Company.

(ii) Delivery of New Warrants Upon Exercise. If this Warrant shall

have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time

of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased

Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant.

(iii) Rescission Rights. If the Company fails to cause the Transfer

Agent to transmit to the Holder the Warrant Shares pursuant to Section 1(d)(i) by the Warrant Share Delivery Date, then the Holder will

have the right to rescind such exercise.

(iv) No Fractional Shares or Scrip. No fractional shares or scrip

representing fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would

otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in respect of such

final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share.

(v) Charges, Taxes and Expenses. Issuance of Warrant Shares shall

be made without charge to the Holder for any issue or transfer tax or other incidental expense in respect of the issuance of such Warrant

Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder

or in such name or names as may be directed by the Holder; provided, however, that, in the event that Warrant Shares are

to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment

Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient

to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day processing

of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar

functions) required for same-day electronic delivery of the Warrant Shares.

(vi) Closing of Books. The Company will not close its shareholder

books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof.

(e) Holder’s Exercise Limitations. Notwithstanding anything

to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and the Holder shall not have

the right to exercise any portion of this Warrant, and any such exercise shall be null and void and cancelled ab initio and treated as

if the exercise had not been made, to the extent that immediately prior to or following such exercise, the Holder, together with the Attribution

Parties, collectively beneficially owns or would beneficially own as determined in accordance with Section 13(d) of the Exchange Act and

the rules promulgated thereunder, in excess of [4.99%]/[9.99%] (the “Maximum Percentage”) of the Common Shares that

would be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for determining whether the

Maximum Percentage is or will be exceeded, the aggregate number of Common Shares held and/or beneficially owned by the Holder together

with the Attribution Parties, shall include the number of Common Shares held and/or beneficially owned by the Holder together with the

Attribution Parties plus the number of Common Shares issuable upon exercise of this Warrant with respect to which the determination is

being made but shall exclude the number of Common Shares which would be issuable upon (i) exercise of the remaining, unexercised portion

of this Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii) exercise or conversion of the unexercised

or unconverted portion of any other securities of the Company held and/or beneficially owned by the Holder or any Attribution Party (including,

without limitation, any convertible notes, convertible shares or warrants) that are subject to a limitation on conversion or exercise

analogous to the limitation contained herein. For purposes of this Section 1(e), beneficial ownership of the Holder or the Attribution

Parties shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with Section 13(d)

of the Exchange Act and the rules promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding Common

Shares, a Holder may rely on the number of outstanding Common Shares as reflected in (1) the Company’s most recent Form 10-K, Form

10-Q, Current Report on Form 8-K or other public filing with the Commission, as the case may be, (2) a more recent public announcement

by the Company or (3) any other notice by the Company or the Transfer Agent setting forth the number of Common Shares outstanding (such

issued and outstanding Common Shares, the “Reported Outstanding Share Number”). For any reason at any time, upon the

written request of the Holder, the Company shall within one (1) Trading Day confirm in writing to the Holder the number of Common Shares

then outstanding. The Holder shall disclose to the Company the number of Common Shares that it, together with the Attribution Parties,

holds and/or beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise

or conversion analogous to the limitation contained herein contemporaneously or immediately prior to submitting a Notice of Exercise for

the relevant Warrant. If the Company receives a Notice of Exercise from the Holder at a time when the actual number of outstanding Common

Shares is less than the Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of Common

Shares then outstanding and, to the extent that such Notice of Exercise would otherwise cause the Holder’s, together with the Attribution

Parties’, beneficial ownership, as determined pursuant to this Section 1(e), to exceed the Maximum Percentage, the Holder must notify

the Company of a reduced number of Warrant Shares to be purchased pursuant to such Notice of Exercise (the number of shares by which such

purchase is reduced, the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to

the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number of outstanding Common Shares shall

be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and

the Attribution Parties since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance

of Common Shares to the Holder upon exercise of this Warrant results in the Holder, together with the Attribution Parties, being deemed

to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding Common Shares (as determined under

Section 13(d) of the Exchange Act), the number of shares so issued by which the Holder’s, together with the Attribution Parties’,

aggregate beneficial ownership exceeds the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and

shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall not have the power to vote or to transfer the Excess

Shares.

As soon as reasonably practicable after the issuance of the Excess Shares has been deemed null and void, the Company shall return

to the Holder the exercise price paid by the Holder for the Excess Shares. By written notice to the Company, a Holder may from time to

time increase or decrease the Maximum Percentage to any other percentage not in excess of 9.99% specified in such notice; provided, that

any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company

and shall not negatively affect any partial exercise effected prior to such change. The provisions of this paragraph shall be construed

and implemented in a manner otherwise than in strict conformity with the terms of this Section 1(e) to the extent necessary to correct

this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation

contained in this Section 1(e) or to make changes or supplements necessary or desirable to properly give effect to such limitation. The

limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant. As used herein, “Affiliate”

means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediates, controls, is controlled

by or is under common control with such Person. “Attribution Parties” means, collectively, the following Persons and

entities: (i) any direct or indirect Affiliates of the Holder, (ii) any investment vehicle, including, any funds, feeder funds or managed

accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder’s investment

manager, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any Attribution Parties and

(iv) any other Persons whose beneficial ownership of the Company’s Common Shares would or could be aggregated with the Holder’s

and/or any other Attribution Parties’ for purposes of Section 13(d) or Section 16 of the Exchange Act. For clarity, the purpose

of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage. “Commission”

means the United States Securities and Exchange Commission. “Exchange Act” means the Securities Exchange Act of 1934,

as amended. “Group” shall have the meaning ascribed to it in Section 13(d) of the Exchange Act, and all related rules,

regulations and jurisprudence. “Person” means an individual, a limited liability company, a partnership, a joint venture,

a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof.

Section 2. Certain Adjustments.

(a) Share Dividends and Splits. If the Company, at any time while

this Warrant is outstanding: (i) pays a share dividend or otherwise makes a distribution or distributions on its Common Shares or any

other equity or equity equivalent securities payable in Common Shares (which, for avoidance of doubt, shall not include any Common Shares

issued by the Company upon exercise, exchange or conversion of the Warrants or any other warrant or exercisable, exchangeable or convertible

securities, and shall not include Purchase Rights for which Section 2(b) shall apply or any distribution of assets for which Section 2(c)

shall apply), (ii) subdivides outstanding Common Shares into a larger number of shares, (iii) combines (including by way of reverse share

split) outstanding Common Shares into a smaller number of shares, or (iv) issues by reclassification of the Common Shares any shares of

share capital of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the

number of Common Shares (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall

be the number of Common Shares outstanding immediately after such event, and the number of shares issuable upon exercise of this Warrant

shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant

to this Section 2(a) shall become effective immediately after the record date for the determination of shareholders entitled to receive

such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination

or re-classification.

(b) Subsequent Rights Offerings. In addition to any adjustments

pursuant to Section 2(a) above, if at any time the Company grants, issues or sells any Common Share Equivalents or rights to purchase

shares, warrants, securities or other property pro rata to the record holders of any class of Common Shares (the “Purchase Rights”),

then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the

Holder could have acquired if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant (without

regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date on which

a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record

holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent

that the Holder’s right to participate in any such Purchase Right would result in the Holder exceeding the Maximum Percentage, then

the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such Common Shares as

a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until

such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage). As used herein, “Common

Share Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time Common

Shares, including, without limitation, any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible

into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.

outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to

holders of Common Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, shares or

other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement

or other similar transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such

case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein

if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations

on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date of which a record is taken for such

Distribution, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined for the participation

in such Distribution (provided, however, that, to the extent that the Holder’s right to participate in any such Distribution would

result in the Holder exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such

extent (or in the beneficial ownership of any Common Shares as a result of such Distribution to such extent) and the portion of such Distribution

shall be held in abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder

exceeding the Maximum Percentage.

(d) Fundamental Transaction. If, at any time while this Warrant

is outstanding, (i) the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the

Company with or into another Person (other than for the purpose of changing the Company’s name and/or the jurisdiction of incorporation

of the Company or a holding company for the Company) , (ii) the Company, directly or indirectly, effects any sale, lease, license, assignment,

transfer, conveyance or other disposition of all or substantially all of the assets of the Company and its subsidiaries, taken as a whole,

in one or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by

the Company or another Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange their

shares for other securities, cash or property and has been accepted by the holders of more than 50% of the outstanding Common Shares,

(iv) the Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization

of the Common Shares or any compulsory share exchange pursuant to which the Common Shares are effectively converted into or exchanged

for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a

share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger

or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding

Common Shares (not including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated

with the other Persons making or party to, such share purchase agreement or other business combination) (each a “Fundamental

Transaction”), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant

Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option

of the Holder (without regard to any limitation in Section 1(e) on the exercise of this Warrant), the number of Common Shares of the successor

or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the “Alternate

Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of Common Shares for which

this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section 1(e) on the

exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted

to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one Common Share in such

Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting

the relative value of any different components of the Alternate Consideration. If holders of Common Shares are given any choice as to

the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the

Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.

The Company shall cause any successor entity in a Fundamental Transaction

in which the Company is not the survivor (the “Successor Entity”) to assume in writing all of the obligations of the

Company under this Warrant in accordance with the provisions of this Section 2(d) pursuant to written agreements in form and substance

reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and

shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by

a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares

of share capital of such Successor Entity (or its parent entity) equivalent to the Common Shares acquirable and receivable upon exercise

of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an

exercise price which applies the exercise price hereunder to such shares of share capital (but taking into account the relative value

of the Common Shares pursuant to such Fundamental Transaction and the value of such shares of share capital, such number of shares of

share capital and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the

consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence

of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of

such Fundamental Transaction, the provisions of this Warrant referring to the “Company” shall refer instead to the Successor

Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant

with the same effect as if such Successor Entity had been named as the Company herein.

(e) Calculations. All calculations under this Section 2 shall be

made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section 2, the number of Common Shares

deemed to be issued and outstanding as of a given date shall be the sum of the number of Common Shares (excluding treasury shares, if

any) issued and outstanding.

(f) Notice to Holder.

(i) Adjustment to Exercise Price. Whenever the Exercise Price is

adjusted pursuant to any provision of this Section 2, the Company shall promptly deliver to the Holder by facsimile or email a notice

setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth

a brief statement of the facts requiring such adjustment.

(ii) Notice to Allow Exercise by Holder. If (A) the Company shall

declare a dividend (or any other distribution in whatever form) on the Common Shares, (B) the Company shall declare a special nonrecurring

cash dividend on or a redemption of the Common Shares, (C) the Company shall authorize the granting to all holders of the Common Shares

rights or warrants to subscribe for or purchase any shares of share capital of any class or of any rights, (D) the approval of any shareholders

of the Company shall be required in connection with any reclassification of the Common Shares, any consolidation or merger to which the

Company (and all of its subsidiaries, taken as a whole) is a party, any sale or transfer of all or substantially all of its assets, or

any compulsory share exchange whereby the Common Shares are converted into other securities, cash or property, or (E) the Company shall

authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company

shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email address as it shall appear upon

the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified,

a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants,

or if a record is not to be taken, the date as of which the holders of the Common Shares of record to be entitled to such dividend, distributions,

redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer

or share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Shares

of record shall be entitled to exchange their Common Shares for securities, cash or other property deliverable upon such reclassification,

consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in

the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the extent that

any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any of the subsidiaries,

the Company shall substantially simultaneously with the giving of such notice, disclose such information with the Commission pursuant

to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of

such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.

(g) Voluntary Adjustment By Company. Subject to the rules and regulations

of the Trading Market, the Company may at any time during the term of this Warrant, subject to the prior written consent of the Holder,

reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the board of directors of the Company.

Section 3. Transfer of Warrant.

(a) Transferability. Subject to compliance with any applicable securities

laws and the conditions set forth in Section 3(d) hereof, this Warrant and all rights hereunder are transferable, in whole or in part,

upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this

Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any

transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute

and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations

specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so

assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required

to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall

surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the

Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for

the purchase of Warrant Shares without having a new Warrant issued.

(b) New Warrants. This Warrant may be divided or combined with other

Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations

in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to compliance with Section 3(a), as to

any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in

exchange for the Warrant or Warrants to be divided or combined in accordance with such notice. All Warrants issued on transfers or exchanges

shall be dated the Initial Exercise Date and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant

thereto.

records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record Holder

hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose

of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

(d) Representation by the Holder. The Holder, by the acceptance

hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable

upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof

in violation of the Securities Act or any applicable state securities law.

Section 4. Miscellaneous.

(a) No Rights as Shareholder Until Exercise; No Settlement in Cash.

This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a shareholder of the Company prior to the

exercise hereof as set forth in Section 1(d)(i), except as expressly set forth in Section 3. Without limiting any rights of a Holder to

receive Warrant Shares on a “cashless exercise” pursuant to Section 1(c) or to receive cash payments pursuant to Section 1(d)(i)

and Section 1(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this Warrant.

(b) Loss, Theft, Destruction or Mutilation of Warrant. The Company

covenants that upon receipt by the Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of

this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security

reasonably satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation

of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock certificate of like tenor

and dated as of such cancellation, in lieu of such Warrant or stock certificate.

day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then such action

may be taken or such right may be exercised on the next succeeding Trading Day.

(d) Authorized Shares.

The Company covenants that, during the period the Warrant is outstanding,

it will reserve from its authorized and unissued Common Shares a sufficient number of shares to provide for the issuance of the Warrant

Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants that its issuance of this Warrant shall

constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the

purchase rights under this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares

may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon

which the Common Shares may be listed. The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase

rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant

Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges

created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring contemporaneously with such

issue).

Except and to the extent as waived or consented to by the Holder, the Company

shall not take any action, including, without limitation, amending its notice of articles or articles or through any reorganization, transfer

of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, in order to avoid or seek to

avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out

of all such terms and in the taking of all such actions as may be necessary to carry out such terms. Without limiting the generality of

the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise

immediately prior to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company

may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially

reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof,

as may be, necessary to enable the Company to perform its obligations under this Warrant.

Before taking any action which would result in an adjustment in the number

of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall use commercially reasonable efforts

to obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies

having jurisdiction thereof.

(e) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION,

VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF

THE STATE OF NEW YORK. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL

COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH

OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT,

ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER

HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING

A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT

FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED

HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER

HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

(f) Restrictions. The Holder acknowledges that the Warrant Shares

acquired upon the exercise of this Warrant will have restrictions upon resale imposed by state and federal securities laws and will bear

a restrictive legend, subject to Section 1(c) in the case of cashless exercise.

(g) Nonwaiver and Expenses. No course of dealing or any delay or

failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder’s

rights, powers or remedies. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply

with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts

as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable and documented out of pocket external

attorneys’ fees of one counsel, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant

hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.

(h) Notices. Any and all notices or other communications or deliveries

hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest

of (i) the date of transmission, if such notice or communication is delivered via confirmed e-mail at the e-mail address specified by

the Company prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission, if such

notice or communication is delivered via confirmed e-mail at the e-mail address specified by the Company on a day that is not a Trading

Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally

recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom such notice

is required to be given, if by hand delivery.

(i) Limitation of Liability. No provision hereof, in the absence

of any affirmative action by the Holder to exercise this Warrant to purchase Warrant Shares, and no enumeration herein of the rights or

privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Shares or as a shareholder

of the Company, whether such liability is asserted by the Company or by creditors of the Company.

(j) Remedies. The Holder, in addition to being entitled to exercise

all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The

Company agrees that monetary damages would not be adequate compensation for any loss incurred by reason of a breach by it of the provisions

of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would

be adequate.

(k) Successors and Assigns. Subject to applicable securities laws,

this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted

assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit

of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

(l) Amendment. This Warrant may be modified or amended or the provisions

hereof waived with the written consent of the Company and the Holder.

(m) Severability. Wherever possible, each provision of this Warrant

shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Warrant shall be prohibited

by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating

the remainder of such provisions or the remaining provisions of this Warrant.

(n) Headings. The headings used in this Warrant are for the convenience

of reference only and shall not, for any purpose, be deemed a part of this Warrant.

********************

(Signature Page Follows)

IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by

its officer thereunto duly authorized as of the date first above indicated.

EDESA BIOTECH INC.

By:

Name:

Title:

NOTICE OF EXERCISE

To: Edesa Biotech Inc. (the “Company”)

(1) The undersigned hereby elects to purchase ________ Warrant Shares of

the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price

in full, together with all applicable transfer taxes, if any.

(2) Payment shall take the form of (check applicable box):

[ ]

in lawful money of the United States; or

[__]

[if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 1(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 1(c).

(3) Please issue said Warrant Shares in the name of the undersigned or

in such other name as is specified below:

The Warrant Shares shall be delivered to the following DWAC Account Number:

By its delivery of this Notice of Exercise, the undersigned represents and warrants to the Company

that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of Common Shares permitted

to be owned under Section 1(e) of the Warrant to which this notice relates.

[SIGNATURE OF HOLDER]

Name of Investing Entity:

Signature of Authorized Signatory of Investing Entity:

Name of Authorized Signatory:

Title of Authorized Signatory:

Date:

ASSIGNMENT FORM

(To assign the foregoing Warrant, execute this form and supply required

information. Do not use this form to purchase shares.)

FOR VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned

Name:

(Please Print)

Address:

(Please Print)

Phone Number:

Email Address:

Dated: _______________ __, ______

Holder’s Signature:

Holder’s Address:

EX-4.2 — EXHIBIT 4.2

EX-4.2

Filename: exh_42.htm · Sequence: 4

Exhibit 4.2

EDESA BIOTECH INC.

FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON SHARES

Number of Shares: [ ]

(subject to adjustment)

Warrant No.

Original Issue Date: August 21, 2026

Edesa Biotech Inc., a British Columbia corporation (the “Company”), hereby

certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered

assigns (the “Holder”), is entitled, subject to the terms set forth below, to purchase from the Company up to a total

of [ ] Common Shares, without par value (the “Common Shares”), of the Company (each such share, a “Warrant

Share” and all such shares, the “Warrant Shares”) at an exercise price per share equal to $0.0001 per share

(as adjusted from time to time as provided in Section 9 herein, the “Exercise Price”), upon surrender of this

Warrant to Purchase Common Shares (including any Warrants to Purchase Common Shares issued in exchange, transfer or replacement hereof,

the “Warrant”) at any time and from time to time on or after the date hereof (the “Original Issue Date”).

This Warrant has been issued pursuant to the terms of the Underwriting Agreement, dated August 19, 2026, between the Company and

Guggenheim Securities, LLC, as the representative of the several underwriters named therein.

Definitions. For purposes of this Warrant, the following terms shall have the following meanings:

(a) “Affiliate” means, with respect to any Person, any

other Person that, directly or indirectly through one or more intermediates, controls, is controlled by or is under common control with

such Person.

(b) “Attribution Parties” means, collectively, the following

Persons and entities: (i) any direct or indirect Affiliates of the Holder, (ii) any investment vehicle, including, any funds, feeder funds

or managed accounts, currently, or from time to time after the date hereof, directly or indirectly managed or advised by the Holder’s

investment manager, (iii) any Person acting or who could be deemed to be acting as a Group together with the Holder or any Attribution

Parties and (iv) any other Persons whose beneficial ownership of the Company’s Common Shares would or could be aggregated with the

Holder’s and/or any other Attribution Parties’ for purposes of Section 13(d) or Section 16 of the Exchange Act. For clarity,

the purpose of the foregoing is to subject collectively the Holder and all other Attribution Parties to the Maximum Percentage.

of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial

Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate the last trade price,

then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the

foregoing do not apply, the last trade price of such security in the over-the-counter market on the electronic bulletin board for such

security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for a security on a particular date

on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined

by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then the

Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors’

determination shall be binding upon all parties absent demonstrable error. All such determinations shall be appropriately adjusted for

any share dividend, share split, share combination or other similar transaction during the applicable calculation period.

(d) “Commission” means the United States Securities

and Exchange Commission.

(e) “Exchange Act” means the Securities Exchange Act

of 1934, as amended.

(f) “Group” shall have the meaning ascribed to it in

Section 13(d) of the Exchange Act, and all related rules, regulations and jurisprudence.

(g) “Person” means an individual, a limited liability

company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or

any department or agency thereof.

(h) “Principal Trading Market” means the national securities

exchange or other trading market on which the Common Shares are primarily listed and quoted for trading, which, as of the Original Issue

Date, shall be the Nasdaq Capital Market.

(i) “Registration Statement” means the Company’s

Registration Statement on Form S-3 (File No. 333-288966), which was declared effective by the Commission on September 9, 2025.

(j) “Securities Act” means the Securities Act of 1933,

as amended.

(k) “Standard Settlement Period” means the standard

settlement period, expressed in a number of Trading Days, for the Principal Trading Market with respect to the Common Shares that is in

effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issue Date was “T+1.”

(l) “Trading Day” means any weekday on which the Principal

Trading Market is normally open for trading.

(m) “Transfer Agent” means Computershare Investor Services

Inc., the Company’s transfer agent and registrar for the Common Shares, and any successor appointed in such capacity.

2. Issuance of Securities; Registration of Warrants. The Warrant, as initially issued

by the Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable

under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration Statement or an exchange

meeting the requirements of Section 3(a)(9) of the Securities Act as in effect on the Original Issue Date, the Warrant Shares, are not

“restricted securities” under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this

Warrant, upon records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the

record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is permissibly assigned

hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the

purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the contrary.

3. Registration of Transfers. This Warrant and all rights hereunder (including, without

limitation, any registration rights) are transferable, in whole or in part, upon surrender of this Warrant at the principal office of

the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly

executed by the Holder or its agent or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer.

Subject to compliance with all applicable securities laws and, if applicable, the rules of the Principal Trading Market, the Company shall,

or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender

of this Warrant, and payment of all applicable transfer taxes (if any). Upon any such registration or transfer, a new warrant to purchase

Common Shares in substantially the form of this Warrant (any such new warrant, a “New Warrant”) evidencing the portion

of this Warrant so transferred shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not

so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall

be deemed the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in

respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own

expense any New Warrant under this Section 3. Until due presentment for registration of transfer, the Company may treat the registered

Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any notice to the contrary.

Exercise and Duration of Warrants.

(a) All or any part of this Warrant shall be exercisable by the registered

Holder in any manner permitted by this Warrant (including Section 11) at any time and from time to time on or after the Original

Issue Date, and such rights shall not expire until exercised in full.

(b) The Holder may exercise this Warrant by delivering to the Company (i)

an exercise notice, in the form attached as Schedule 1 hereto (the “Exercise Notice”), completed and duly signed,

and (ii) payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being exercised (which may take the

form of a “cashless exercise” if so indicated in the Exercise Notice pursuant to Section 10 below), and the date on

which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an “Exercise

Date.” The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution

and delivery of the Exercise Notice shall have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing

the right to purchase the remaining number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge

and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the

number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

Delivery of Warrant Shares.

(a) Upon exercise of this Warrant, the Company shall promptly (but in no

event later than the number of Trading Days comprising the Standard Settlement Period following the Exercise Date; provided, that

if any day within the Standard Settlement Period is a day on which banks in British Columbia, Canada are not open for business, the Standard

Settlement Period shall be extended by one Trading Day for each such day), upon the request of the Holder, credit such aggregate number

of Common Shares specified by the Holder in the Exercise Notice and to which the Holder is entitled pursuant to such exercise (the “Exercise

Shares”) to the Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”)

through its Deposit Withdrawal At Custodian system, or if the Transfer Agent is then a participant in the DTC Fast Automated Securities

Transfer Program (the “FAST Program”) and either (A) there is an effective registration statement permitting the issuance

of the Warrant Shares to or the resale of such Warrant Shares by the Holder or (B) the Exercise Shares are eligible for resale by the

Holder without volume or manner-of-sale restrictions pursuant to Rule 144 promulgated under the Securities Act (assuming cashless exercise

of this Warrant). If the Transfer Agent is not a member of the FAST Program or if (A) and (B) above are not true, the Transfer Agent will

either (i) record the Exercise Shares in the name of the Holder or its designee on the certificate(s) reflecting the Exercise Shares with

an appropriate legend regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address

as specified in the Exercise Notice, and on the Company’s share register or (ii) issue such Exercise Shares in the name of the Holder

or its designee in restricted book-entry form in the Company’s share register. The Holder, or any Person so designated by the Holder

to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective

of the date such Warrant Shares are credited to the Holder’s DTC account, the date of the book entry positions or the date of delivery

of the certificate(s) evidencing such Exercise Shares, as the case may be.

(b) If the Company fails to deliver to the Holder or its designee Exercise

Shares in the manner required pursuant to Section 5(a) within the Standard Settlement Period following the Exercise Date (other than a

failure caused by incorrect or incomplete information provided by the Holder to the Company) and the Holder purchases (in an open market

transaction or otherwise) Common Shares to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated

receiving upon such exercise (a “Buy-In”) but did not receive within the Standard Settlement Period, then the Company

shall, within three (3) Trading Days after the Holder’s request and in the Holder’s sole discretion, either (1) pay in cash

to the Holder an amount equal to the Holder’s total purchase price (including brokerage commissions, if any) for the Common Shares

so purchased, at which point the Company’s obligation to issue and deliver such Exercise Shares shall terminate or (2) promptly

honor its obligation to deliver to the Holder or its designee the Exercise Shares pursuant to Section 5(a) and pay cash to the Holder

in an amount equal to the excess (if any) of Holder’s total purchase price (including brokerage commissions, if any) for the Common

Shares so purchased in the Buy-In, less the product of (A) the number of Common Shares purchased in the Buy-In, times (B) the Closing

Sale Price of a Common Share on the Exercise Date.

the Company’s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the

limitations set forth in Section 11 below) are absolute and unconditional, irrespective of any action or inaction by the Holder

to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any

action to enforce the same, or any setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the

Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person,

and irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with

the issuance of Warrant Shares. Subject to Section 5(b), nothing herein shall limit the Holder’s right to pursue any other

remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive

relief with respect to the Company’s failure to timely deliver Common Shares upon exercise of the Warrant as required pursuant to

the terms hereof; provided, however, that the Holder shall not be entitled to both (i) require the Company to reinstate

the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not timely honored and (ii) receive the

number of Common Shares that would have been issued if the Company had timely complied with its delivery requirements under Section 5(a).

6. Charges, Taxes and Expenses. Issuance and delivery of Common Shares upon exercise

of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or

expense (excluding any applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall

be paid by the Company; provided, however, that the Company shall not be required to pay any tax that may be payable in

respect of any transfer involved in the registration of any Warrant Shares or the Warrants in a name other than that of the Holder or

an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring

this Warrant or receiving Warrant Shares upon exercise hereof.

7. Replacement of Warrant. If this Warrant is mutilated, lost, stolen or destroyed, the

Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution

for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction

(in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by the Company. Applicants for a New

Warrant under such circumstances shall also comply with such other reasonable regulations and procedures as the Company may prescribe.

If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the

Company as a condition precedent to the Company’s obligation to issue the New Warrant.

8. Reservation of Warrant Shares. The Company covenants that it will, at all times while

this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common

Shares, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of

Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any

other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of Section

9). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable

Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and non-assessable. The Company

will take all such action as may be reasonably necessary to assure that such Common Shares may be issued as provided herein without violation

of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common

Shares may be listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions

to increase the par value of the Common Shares at any time while this Warrant is outstanding.

9. Certain Adjustments. The Exercise Price and number of Warrant Shares issuable upon

exercise of this Warrant (the “Number of Warrant Shares”) are subject to adjustment from time to time as set forth in this

Section 9.

(a) Share Dividends and Splits. If the Company, at any time while

this Warrant is outstanding, (i) pays a stock dividend on its Common Shares or otherwise makes a distribution on any class of share capital

issued and outstanding on the Original Issue Date and in accordance with the terms of such shares on the Original Issue Date or as amended,

that is payable in Common Shares, (ii) subdivides its outstanding Common Shares into a larger number of Common Shares, (iii) combines

its outstanding Common Shares into a smaller number of Common Shares or (iv) issues by reclassification of shares of share capital any

additional Common Shares of the Company, then in each such case the Number of Warrant Shares shall be multiplied by a fraction, the numerator

of which shall be the number of Common Shares outstanding immediately after such event and the denominator of which shall be the number

of Common Shares outstanding immediately before such event. Any adjustment made pursuant to clause (i) of this paragraph shall become

effective immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution, provided,

however, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Number of

Warrant Shares shall be recomputed accordingly as of the close of business on such record date and thereafter the Number of Warrant Shares

shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)

or (iii) of this paragraph shall become effective immediately after the effective date of such subdivision or combination.

(b) Pro Rata Distributions. If, on or after the Original Issue Date,

the Company shall declare or make any dividend or other pro rata distribution of its assets (or rights to acquire its assets) to holders

of Common Shares, by way of return of capital or otherwise (including, without limitation, any distribution of cash, share or other securities,

property, options, evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement,

scheme of arrangement or other similar transaction, but, for the avoidance of doubt, excluding any distribution of Common Shares subject

to Section 9(a), any distribution of Purchase Rights (as defined below) subject to Section 9(c) and any Fundamental Transaction

(as defined below) subject to Section 9(d)) (a “Distribution”) then, in each such case, the Holder shall be

entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held

the number of Common Shares acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise

of this Warrant, including without limitation, the Maximum Percentage (as defined below)) immediately before the date on which a record

is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Shares are to be determined

for the participation in such Distribution (provided, that to the extent that the Holder’s right to participate in any such Distribution

would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to

participate in such Distribution to such extent (and shall not be entitled to beneficial ownership of such Common Shares as a result of

such Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit

of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding

the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on

such initial Distribution or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such

limitation).

Date, the Company grants, issues or sells any Options, Convertible Securities or rights to purchase shares, warrants, securities or other

property, in each case pro rata to the record holders of any class of Common Shares (the “Purchase Rights”), then the

Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder

could have acquired if the Holder had held the number of Common Shares acquirable upon complete exercise of this Warrant (without regard

to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before

the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date

as of which the record holders of Common Shares are to be determined for the grant, issuance or sale of such Purchase Rights (provided,

that to the extent that the Holder’s right to participate in any such Purchase Right would result in the Holder and the other Attribution

Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Purchase Right to such extent (and

shall not be entitled to beneficial ownership of such Common Shares as a result of such Purchase Right (and beneficial ownership) to such

extent) and such Purchase Right to such extent shall be held in abeyance for the benefit of the Holder until such time or times as its

right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times

the Holder shall be granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent

Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation). As used in this Section

9(c), (i) “Options” means any rights, warrants or options to subscribe for or purchase Common Shares or Convertible Securities

and (ii) “Convertible Securities” mean any shares or securities (other than Options) directly or indirectly convertible into

or exercisable or exchangeable for Common Shares.

(d) Fundamental Transactions. If, at any time while this Warrant

is outstanding (i) the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is

not the surviving entity or in which the shareholders of the Company immediately prior to such merger or consolidation do not own, directly

or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii) the Company

effects any sale to another Person of all or substantially all of its assets in one or a series of related transactions, (iii) pursuant

to any tender offer or exchange offer (whether by the Company or another Person), holders of share capital tender shares representing

more than 50% of the voting power of the share capital of the Company and the Company or such other Person, as applicable, accepts such

tender for payment, (iv) the Company consummates a share purchase agreement or other business combination (including, without limitation,

a reorganization, recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than

50% of the voting power of the share capital of the Company (except for any such transaction in which the shareholders of the Company

immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after

the transaction) or (v) the Company effects any reclassification of the Common Shares or any compulsory share exchange pursuant to which

the Common Shares are effectively converted into or exchanged for other securities, cash or property (other than as a result of a subdivision

or combination of Common Shares covered by Section 9(a) above) (in any such case, a “Fundamental Transaction”),

then following such Fundamental Transaction the Holder shall have the right to receive, upon exercise of this Warrant, the same amount

and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction

if it had been, immediately prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise

in full of this Warrant without regard to any limitations on exercise contained herein (the “Alternate Consideration”).

The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration

includes securities of another Person unless (i) the Alternate Consideration is solely cash and the Company provides for the simultaneous

“cashless exercise” of this Warrant pursuant to Section 10 below or (ii) prior to, simultaneously with or promptly

following the consummation thereof, any successor to the Company, surviving entity or other Person (including any purchaser of assets

of the Company) assumes the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions,

the Holder may be entitled to receive, and the other obligations under this Warrant. The provisions of this paragraph (d) shall similarly

apply to subsequent transactions analogous to a Fundamental Transaction.

(e) Number of Warrant Shares. Simultaneously with any adjustment

to the Exercise Price pursuant to Section 9, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall

be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased

or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.

(f) Calculations. All calculations under this Section 9 shall

be made to the nearest one-tenth of one cent or the nearest share, as applicable.

(g) Notice of Adjustments. Upon the occurrence of each adjustment

pursuant to this Section 9, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment,

in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement

of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant

(as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment

is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Company’s

transfer agent.

(h) Notice of Corporate Events. If, while this Warrant is outstanding,

the Company (i) declares a dividend or any other distribution of cash, securities or other property in respect of its Common Shares, including,

without limitation, any granting of rights or warrants to subscribe for or purchase any share capital of the Company or any subsidiary,

(ii) authorizes or approves, enters into any agreement contemplating or solicits shareholder approval for any Fundamental Transaction

or (iii) authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company, then, except if such notice and

the contents thereof shall be deemed to constitute material non-public information, the Company shall deliver to the Holder a notice of

such transaction at least ten (10) days prior to the applicable record or effective date on which a Person would need to hold Common Shares

in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice

or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while

this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits shareholder approval

for any Fundamental Transaction contemplated by Section 9(d), other than a Fundamental Transaction under clause (iii) of Section

9(d), then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company

shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental Transaction

is consummated. Holder agrees to maintain any information disclosed pursuant to this Section 9(h) in confidence until such information

is publicly available, and shall comply with applicable law with respect to trading in the Company’s securities following receipt

of any such information.

10. Payment of Exercise Price. Notwithstanding anything contained herein to the contrary,

the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a “cashless exercise”, in

which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section

3(a)(9) of the Securities Act, as determined as follows:

X = Y [(A-B)/A]

where:

“X” equals the number of Warrant Shares to be issued to the Holder;

“Y” equals the total number of Warrant Shares with respect to which this Warrant

is then being exercised;

“A” equals the Closing Sale Price of the Common Shares (as

reported by Bloomberg Financial Markets) as of the Trading Day on the date immediately preceding the Exercise Date; and

“B” equals the Exercise Price then in effect for the applicable Warrant Shares at

the time of such exercise.

For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and

acknowledged that the Warrant Shares issued in a “cashless exercise” transaction shall be deemed to have been acquired by

the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued

(provided, that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the

event that the Registration Statement or another registration statement registering the issuance of Warrant Shares is, for any reason,

not effective at the time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth

in this Section 10. If the Warrant Shares are issued in such a cashless exercise, the Company acknowledges and agrees that, in

accordance with Section 3(a)(9) of the Securities Act, the Exercise Shares issued in such exercise shall take on the registered characteristics

of the Warrants being exercised and may be tacked on to the holding period of the Warrants being exercised. Except as set forth in Section

5(b) (Buy-In remedy) and Section 12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant

be settled in cash.

11.

Limitations on Exercise.

(a) Notwithstanding anything to the contrary contained herein, the Company

shall not effect the exercise of any portion of this Warrant, and the Holder of the Warrant shall not have the right to exercise any portion

of the Warrant, and any such exercise shall be null and void and cancelled ab initio and treated as if the exercise had not been made,

to the extent that immediately prior to or following such exercise, the Holder, together with the Attribution Parties, collectively beneficially

owns or would beneficially own as determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated thereunder,

in excess of [4.99%]/[9.99%] (the “Maximum Percentage”) of the Common Shares that would be issued and outstanding following

such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum Percentage is or will be exceeded,

the aggregate number of Common Shares held and/or beneficially owned by the Holder together with the Attribution Parties, shall include

the number of Common Shares held and/or beneficially owned by the Holder together with the Attribution Parties plus the number of Common

Shares issuable upon exercise of the relevant Warrant with respect to which the determination is being made but shall exclude the number

of Common Shares which would be issuable upon (i) exercise of the remaining, unexercised Warrant held and/or beneficially owned by the

Holder or the Attribution Parties and (ii) exercise or conversion of the unexercised or unconverted portion of any other securities of

the Company held and/or beneficially owned by such Holder or any Attribution Party (including, without limitation, any convertible notes,

convertible shares or warrants) that are subject to a limitation on conversion or exercise analogous to the limitation contained herein.

For purposes of this Section 11(a), beneficial ownership of the Holder or the Attribution Parties shall, except as set forth in

the immediately preceding sentence, be calculated and determined in accordance with Section 13(d) of the Exchange Act and the rules promulgated

thereunder. For purposes of the Warrant, in determining the number of outstanding Common Shares, a Holder of the Warrant may rely on the

number of outstanding Common Shares as reflected in (1) the Company’s most recent Form 10-K, Form 10-Q, Current Report on Form 8-K

or other public filing with the Commission, as the case may be, (2) a more recent public announcement by the Company or (3) any other

notice by the Company or the Company’s transfer agent setting forth the number of Common Shares outstanding (such issued and outstanding

Common Shares, the “Reported Outstanding Share Number”). For any reason at any time, upon the written request of the

Holder, the Company shall within one (1) Business Day confirm in writing to the Holder the number of Common Shares then outstanding. The

Holder shall disclose to the Company the number of Common Shares that it, together with the Attribution Parties holds and/or beneficially

owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise or conversion analogous

to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise Notice for the relevant Warrant. If

the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding Common Shares is less than the

Reported Outstanding Share Number, the Company shall (i) notify the Holder in writing of the number of Common Shares then outstanding

and, to the extent that such Exercise Notice would otherwise cause the Holder’s, together with the Attribution Parties’, beneficial

ownership, as determined pursuant to this Section 11(a), to exceed the Maximum Percentage, the Holder must notify the Company of

a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced,

the “Reduction Shares”) and (ii) as soon as reasonably practicable, the Company shall return to the Holder any exercise

price paid by the Holder for the Reduction Shares. In any case, the number of outstanding Common Shares shall be determined after giving

effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder and the Attribution Parties since

the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Shares to the Holder

upon exercise of this Warrant results in the Holder, together with the Attribution Parties, being deemed to beneficially own, in the aggregate,

more than the Maximum Percentage of the number of outstanding Common Shares (as determined under Section 13(d) of the Exchange Act), the

number of shares so issued by which the Holder’s, together with the Attribution Parties’, aggregate beneficial ownership exceeds

the Maximum Percentage (the “Excess Shares”) shall be deemed null and void and shall be cancelled ab initio, and the

Holder and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable

after the issuance of the Excess Shares has been deemed null and void, the Company shall return to the Holder the exercise price paid

by the Holder for the Excess Shares. By written notice to the Company, a Holder of the Warrant may from time to time increase or decrease

the Maximum Percentage to any other percentage not in excess of 9.99% specified in such notice; provided, that any increase in

the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company and shall

not negatively affect any partial exercise effected prior to such change.

(b) This Section 11 shall not restrict the number of Common Shares

which a Holder or the Attribution Parties may receive or beneficially own in order to determine the amount of securities or other consideration

that such Holder or the Attribution Parties may receive in the event of a Fundamental Transaction as contemplated in Section 9(d)

of this Warrant. For purposes of clarity, the Common Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage

shall not be deemed to be beneficially owned by the Holder or the Attribution Parties for any purpose including for purposes of Section

13(d) of the Exchange Act and the rules promulgated thereunder or Section 16 of the Exchange Act and Rule 16a-1(a)(1) promulgated thereunder.

No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of

this paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and

implemented in a manner otherwise than in strict conformity with the terms of this Section 11(a) to the extent necessary to correct

this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation

contained in this Section 11(a) or to make changes or supplements necessary or desirable to properly give effect to such limitation.

The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this Warrant.

12. No Fractional Shares. No fractional Warrant Shares will be issued in connection with

any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued

shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing

Sale Price) for any such fractional shares.

13. Notices. Any and all notices or other communications or deliveries hereunder (including,

without limitation, any Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i) the date of

transmission, if such notice or communication is delivered via confirmed e-mail at the e-mail address specified in the books and records

of the warrant agent prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission,

if such notice or communication is delivered via confirmed e-mail at the e-mail address specified in the books and records of the warrant

agent on a day that is not a Trading Day or later than 5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following

the date of mailing, if sent by United States Express Mail or a nationally recognized overnight courier service, in each case specifying

next business day delivery, or (iv) upon actual receipt by the Person to whom such notice is required to be given, if by hand delivery.

14. Warrant Agent. The Company shall initially serve as warrant agent under this Warrant.

Upon thirty (30) days’ notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company

or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent

shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or

shareholder services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant

agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder

at the Holder’s last address as shown on the Warrant Register.

15.

Miscellaneous.

(a) No Rights as a Shareholder. Except as otherwise set forth in

this Warrant, the Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive

dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed

to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a shareholder of

the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of shares, reclassification

of shares, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription

rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the

due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder

to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company, whether such liabilities are

asserted by the Company or by creditors of the Company.

(b) Authorized Shares. (i) Except and to the extent as waived or

consented to by the Holder, the Company shall not by any action, including, without limitation, amending its Notice of Articles or Articles

or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary

action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith

assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights

of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (1) not

increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in

par value, (2) take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid

and non-assessable Warrant Shares upon the exercise of this Warrant, and (3) use commercially reasonable efforts to obtain all such authorizations,

exemptions or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform

its obligations under this Warrant.

(ii) Before taking any action which would result in an adjustment in the number of Warrant Shares

for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof,

or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof.

securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent

of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on and inure to the benefit

of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant

shall be construed to give to any Person other than the Company and the Holder any legal or equitable right, remedy or cause of action

under this Warrant.

(d) Amendment and Waiver. This Warrant may be amended only in writing

signed by the Company and the Holder, or their successors and assigns. Except as otherwise provided herein, Company may take any action

herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent

of the Holder.

(e) Acceptance. Receipt of this Warrant by the Holder shall constitute

acceptance of and agreement to all of the terms and conditions contained herein.

(f) Governing Law; Jurisdiction. ALL QUESTIONS CONCERNING THE CONSTRUCTION,

VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF

THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY

SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION

OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT

TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR

PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY

IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING

A COPY THEREOF VIA REGISTERED OR CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT

FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED

HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER

HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY.

(g) Headings. The headings herein are for convenience only, do not

constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions hereof.

(h) Severability. If any part or provision of this Warrant is held

unenforceable or in conflict with the applicable laws or regulations of any jurisdiction, the invalid or unenforceable part or provisions

shall be replaced with a provision which accomplishes, to the extent possible, the original business purpose of such part or provision

in a valid and enforceable manner, and the remainder of this Warrant shall remain binding upon the parties hereto.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed

by its authorized officer as of the date first indicated above.

EDESA BIOTECH INC.

By:

Name:

Title:

[Signature Page to Pre-Funded Warrant]

SCHEDULE 1

FORM OF EXERCISE NOTICE

[To be executed by the Holder to purchase Common Shares under the Warrant]

Ladies and Gentlemen:

(1) The undersigned is the Holder of Warrant No. (the “Warrant”) issued by Edesa

Biotech Inc., a British Columbia corporation (the “Company”). Capitalized terms used herein and not otherwise defined herein

have the respective meanings set forth in the Warrant.

(2) The undersigned hereby exercises its right to purchase

Warrant Shares pursuant to the Warrant.

(3) The Holder intends that payment of the Exercise Price shall be made as (check one):

☐

Cash Exercise

☐

“Cashless Exercise” under Section 10 of the Warrant

(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $

in immediately available funds to the Company in accordance with the terms of the Warrant.

(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares

determined in accordance with the terms of the Warrant. The Warrant Shares shall be delivered to the following DWAC Account Number: .

(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the

Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of Common

Shares (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under

Section 11(a) of the Warrant to which this notice relates.

Dated:

Name of Holder:

By:

Name:

Title:

(Signature must conform in all respects to name of Holder as specified on

the face of the Warrant)

EX-5.1 — EXHIBIT 5.1

EX-5.1

Filename: exh_51.htm · Sequence: 5

Exhibit 5.1

August 20, 2026

Edesa Biotech, Inc.

100 Spy Court

Markham, ON L3R 5H6

Canada

Dear Sirs/Mesdames:

Re: Edesa Biotech, Inc. – Registered Offering of Securities

We have acted as Canadian legal counsel to Edesa Biotech,

Inc., a British Columbia corporation (the “Company”), in connection with the sale (the “Offering”)

by the Company of (i) 3,870,500 common shares in the capital of the Company (the “Offered Shares”), (ii) 675,000 pre-funded

warrants (the “Pre-Funded Warrants”) to purchase up to 675,000 common shares in the capital of the Company, and (iii)

warrants to purchase up to 4,545,500 common shares in the capital of the Company (the “Common Warrants”, and together

with the Offered Shares and the Pre-Funded Warrants, the “Securities”) to be sold under a prospectus supplement filed

by the Company with the United States Securities and Exchange Commission (“SEC”) on August 20, 2026 (the “Prospectus

Supplement”) pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “Act”), supplementing

the Company’s existing shelf registration statement on Form S-3 (File No. 333-288966) filed by the Company with the SEC, which was

declared effective by the SEC on September 9, 2025 (the “Registration Statement”) and the prospectus contained therein

(the “Base Prospectus”, and together with the Prospectus Supplement, the “Prospectus”). The common

shares underlying the Pre-Funded Warrants and the Common Share Warrants are herein referred to as “Warrant Shares”.

The Offering is to be made pursuant to the terms of an

underwriting agreement (the “Underwriting Agreement”) between the Company and Guggenheim Securities, LLC, as representative

of several underwriters named therein.

We have reviewed, but not participated in the preparation

of: (i) the Registration Statement; (ii) the Prospectus; and (iii) the Underwriting Agreement.

We have examined originals or certified copies of such

corporate records, documents, certificates and instruments as we have deemed relevant and necessary for the basis of our opinions hereinafter

expressed. In such examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity

of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or

certified or conformed copies, and the authenticity of originals or such latter documents. As to various questions of fact material to

such opinion that we have not independently established or verified, information with respect to which is in possession of the Company,

we have relied upon certificates and other records and certificates of officers of the Company, including a certificate of an officer

of the Company, dated the date hereof, certifying certain factual matters including, among other things: (i) the notice of articles and

articles of the Company; (ii) the incumbency of certain officers of the Company; and (iii) resolutions passed by the directors of the

Company approving, among other things, the execution, delivery and performance by the Company of its obligations under the Underwriting

Agreement. In making our examination of executed documents or documents to be executed, we have assumed that the parties thereto, including

the Company, had or will have the power, corporate or other, to enter into and perform all obligations thereunder and have also assumed

the due authorization by all requisite action, corporate or other, and execution and delivery by such parties of such documents and, the

validity and binding effect on all such parties.

In rendering our opinions set forth herein, we have also

assumed that (i) the Company has been duly organized and is validly existing and in good standing, and has the requisite legal status

and legal capacity, under the laws of the Province of British Columbia; (ii) the Company has complied and will comply with the laws of

all relevant jurisdictions in connection with the transactions contemplated by, and the performance of its obligations under, the Registration

Statement and the Underwriting Agreement; (iii) the Registration Statement and any amendments thereto (including any post-effective amendments

thereto) has become effective under the Act; (iv) the Underwriting Agreement will have been duly authorized and validly executed and delivered

by any party thereto other than the Company, and will be filed with the SEC on a Current Report on Form 8-K or other applicable periodic

report in the manner contemplated in the Registration Statement and the Prospectus Supplement; and (v) that the Securities will be issued

and sold in compliance with applicable U.S. federal and state securities laws and in the manner stated in the Registration Statement,

the Prospectus Supplement and the Underwriting Agreement. As to any facts material to our opinion, we have made no independent investigation

of such facts and have relied, to the extent that we deem such reliance proper, upon certificates of public officials and officers or

other representatives of the Company.

Based solely upon and subject to the foregoing, and subject

to the assumptions, limitations, exceptions and qualifications stated herein, we are of the opinion that:

(i) with respect to any Offered Shares, when such Offered Shares have been issued and delivered against payment

therefor in accordance with the terms of the Underwriting Agreement, with certificates representing such Offered Shares having been duly

executed, countersigned, registered and delivered or, if uncertificated, valid book-entry notations therefor having been made in the central

securities register of the Company, in accordance with the terms of the Underwriting Agreement, the Offered Shares will be validly issued,

fully paid and non-assessable;

(ii) the Company has taken all necessary corporate action to duly and validly authorize the issuance of the Pre-Funded Warrants and the Common Warrants, and when such Pre-Funded Warrants and Common Warrants have been issued and delivered against payment therefor in accordance with the terms of the Underwriting Agreement, the Pre-Funded Warrants and the Common Warrants will have been duly and validly created and issued by the Company; and

(iii) with respect to any Warrant Shares, when such Warrant Shares have been issued and delivered against payment of the exercise price therefor in accordance with the terms of the instrument representing the Pre-Funded Warrants or the Common Warrants, as applicable, with certificates representing such Warrant Shares having been duly executed, countersigned, registered and delivered or, if uncertificated, valid book-entry notations therefor having been made in the central securities register of the Company, in accordance with the terms of the instrument representing the Pre-Funded Warrant or the Common Warrants, as applicable, the Warrant Shares will be validly issued by the Company as fully paid and non-assessable common shares in the capital of the Company.

The matters expressed in this letter are subject to and

qualified and limited by (i) the effects of bankruptcy, insolvency, fraudulent conveyance, reorganization, arrangement, moratorium or

other similar laws now or hereafter in effect relating to or affecting creditors’ rights generally; (ii) the effects of general

equitable principles, including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing, and the possible

unavailability of specific performance or injunctive relief, whether enforcement is considered in a proceeding in equity or law; (iii)

the discretion of the court before which any proceeding for enforcement may be brought; and (iv) the unenforceability under certain circumstances

under law or court decisions of provisions providing for the indemnification of or contribution to a party with respect to a liability

where such indemnification or contribution is contrary to the public policy. We express no opinion as to the sufficiency of any consideration

to be paid for any Offered Shares or actual receipt of such consideration.

We are qualified to practice law in the Province of British

Columbia, and we do not purport to be experts on the law of any other jurisdiction other than the Province of British Columbia and the

federal laws of Canada applicable therein. We do not express any opinion herein concerning any law other than the laws of the Province

of British Columbia and the federal laws of Canada applicable therein. This opinion is expressed as of the date hereof unless otherwise

expressly stated, and we disclaim any undertaking to advise you of any subsequent changes of the facts stated or assumed herein or any

subsequent changes in applicable law.

We hereby consent to the filing of this opinion as an

exhibit to the Registration Statement and the use of our firm name where it appears in each of the Prospectus and the Prospectus Supplement

under the caption “Legal Matters”. In giving this consent, we do not admit that we are included in the category of persons

whose consent is required under Section 7 of the Act or the rules and regulations promulgated thereunder.

Yours truly,

“Fasken Martineau DuMoulin LLP”

FASKEN MARTINEAU DuMOULIN LLP

EX-5.2 — EXHIBIT 5.2

EX-5.2

Filename: exh_52.htm · Sequence: 6

Exhibit 5.2

August 20, 2026

Edesa Biotech, Inc.

100 Spy Court,

Markham, Ontario, Canada L3R 5H6

Ladies and Gentlemen:

We have acted as counsel to Edesa Biotech, Inc., a

corporation organized under the laws of British Columbia, Canada (the “Company”), in connection with the preparation

and filing of (i) the Registration Statement on Form S-3 (Registration No. 333-288966) (the “Registration Statement”),

which was declared effective on September 9, 2025, with the Securities and Exchange Commission (the “Commission”) under

the Securities Act of 1933, as amended (the “Securities Act”), and the related base prospectus contained in the Registration

Statement dated September 9, 2025 (the “Base Prospectus”) and (ii) the prospectus supplement to the Registration Statement,

dated August 19, 2026 (the “Prospectus Supplement”) relating to the issuance and sale by the Company of 4,552,325 of

the Company’s common shares, without par value (the “Common Shares” and such shares, the “Shares”),

Pre-Funded Warrants (the “Pre-Funded Warrants”) to purchase up to an aggregate of 675,000 Common Shares (the “Pre-Funded

Warrant Shares”) and Common Share Warrants (the “Common Warrants” and together with the Pre-Funded Warrants,

the “Warrants”) to purchase up to an aggregate of 5,227,325 Common Shares (the “Common Warrant Shares”

and together with the Pre-Funded Warrant Shares, the “Warrant Shares”) (including 681,825 Common Shares and Common

Warrants to purchase up to 681,825 Common Shares issuable by the Company upon exercise of an option to purchase additional securities

granted by the Company to the Underwriters (as defined below)).

The Shares and Warrants are to be sold pursuant to

an Underwriting Agreement, dated August 19, 2026 (the “Underwriting Agreement”), between the Company and Guggenheim

Securities, LLC, as representative of the several underwriters named in Schedule 1 therein (the “Underwriters”). We

have been requested by the Company to render this opinion in connection with the filing of the Current Report on Form 8-K with respect

to the sale and issuance by the Company of the Warrants (the “Form 8-K”).

As counsel to the Company in connection with the issuance

and sale of the above-referenced Shares, Warrants and Warrant Shares, we have reviewed the Registration Statement, Base Prospectus, Prospectus

Supplement and the respective exhibits thereto, the Underwriting Agreement, the Form of Pre-Funded Warrant and the Form of Common Warrant.

We have also reviewed such corporate documents and records of the Company, such certificates of public officials and officers of the Company

and such other matters as we have deemed necessary or appropriate for purposes of this opinion. In our examination, we have assumed: (i)

the authenticity of original documents and the genuineness of all signatures; (ii) the conformity to the originals of all documents submitted

to us as copies; (iii) the truth, accuracy and completeness of the information, representations and warranties contained in the instruments,

documents, certificates and records we have reviewed; (iv) that, as set forth in a separate opinion delivered to the Company on the date

hereof by Fasken Martineau DuMoulin LLP, Canadian counsel for the Company, the Shares, the Warrants and the Warrant Shares have been duly

authorized; and (v) the legal capacity for all purposes relevant hereto of all natural persons and, with respect to all parties to agreements

or instruments relevant hereto other than the Company, that such parties had the requisite power and authority (corporate or otherwise)

to execute, deliver and perform such agreements or instruments, that such agreements or instruments have been duly authorized by all requisite

action (corporate or otherwise), executed and delivered by such parties and that such agreements or instruments are the valid, binding

and enforceable obligations of such parties. As to any facts material to the opinions expressed herein that were not independently established

or verified, we have relied upon oral or written statements and representations of officers and other representatives of the Company.

Based on the foregoing, and subject to the assumptions, limitations and qualifications set

forth herein, we are of the opinion that when the Warrants are duly executed and delivered by the Company and paid for by the Underwriters

pursuant to the Underwriting Agreement, such Warrants will constitute the legal, valid and binding obligation of the Company, enforceable

against the Company in accordance with their terms, subject to bankruptcy, insolvency or other similar laws affecting creditors’

rights and to general equitable principles.

The opinion set forth above is subject to the following

exceptions, limitations and qualifications: (i) the effect of bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium

or other similar laws now or hereafter in effect relating to or affecting the rights and remedies of creditors; (ii) the effect of general

principles of equity, including without limitation, concepts of materiality, reasonableness, good faith and fair dealing and the possible

unavailability of specific performance or injunctive relief, regardless of whether enforcement is considered in a proceeding in equity

or at law, and the discretion of the court before which any proceeding therefor may be brought; and (iii) the unenforceability under certain

circumstances under law or court decisions of provisions providing for the indemnification of, or contribution to, a party with respect

to liability where such indemnification or contribution is contrary to public policy. We express no opinion concerning the enforceability

of any waiver of rights or defenses with respect to stay, extension or usury laws.

Our opinion is limited to the laws of New York. We

express no opinion as to the effect of the law of any other jurisdiction. Our opinion is rendered as of the date hereof, and we assume

no obligation to advise you of changes in law or fact (or the effect thereof on the opinions expressed herein) that hereafter may come

to our attention. We advise you that matters of Canadian law are covered in the opinion of Fasken Martineau DuMoulin LLP, Canadian counsel

for the Company, in Exhibit 5.1 to the Form 8-K.

We hereby consent to the inclusion of this opinion

as Exhibit 5.2 to the Form 8-K and to the references to our firm in the Prospectus Supplement under the caption “Legal Matters.”

In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities

Act or the rules and regulations thereunder.

Very truly yours,

/s/ Lowenstein Sandler LLP

Lowenstein Sandler LLP

-2-

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: exh_991.htm · Sequence: 7

EdgarFiling

EXHIBIT 99.1

Edesa Biotech Announces Proposed Public Offering

Guggenheim Securities is acting as the sole book-running manager for the proposed offering.

Edesa intends to use the net proceeds from the proposed offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-288966), including a base prospectus, that was declared effective by the Securities and Exchange Commission (“SEC”) on September 9, 2025. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and will be available for free on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may be obtained, when available, from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. The final terms of the public offering will be disclosed in a final prospectus supplement filed with the SEC.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.

About Edesa Biotech, Inc.

Edesa Biotech, Inc. (Nasdaq: EDSA) is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Its clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. In Medical Dermatology, Edesa is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase 3-ready asset developed for use as a potential therapy for moderate-to-severe chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The Company’s most advanced Respiratory drug candidate is paridiprubart, which is being developed as a potential treatment for Acute Respiratory Distress Syndrome, a life-threatening form of respiratory failure. The paridiprubart program has been the recipient of two funding awards from the Government of Canada to support the further development of this asset, and is currently being evaluated in a U.S. government-funded platform study. Edesa is also pursuing additional uses for paridiprubart.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “will,” “would,” “could,” “should,” “might,” “potential,” or “continue” and variations or similar expressions, including statements regarding the completion, timing and size of the proposed offering, Edesa’s intent to grant the underwriters a 30-day option to purchase additional shares and common share warrants and the anticipated use of proceeds from the proposed offering. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: market and other conditions, those relating to the anticipated use of proceeds, the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa’s operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa’s product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the Company’s ability to control or predict. For a discussion of further risks and uncertainties related to Edesa’s business, please refer to Edesa’s reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contact:

Gary Koppenjan

Edesa Biotech, Inc.

investors@edesabiotech.com

EX-99.2 — EXHIBIT 99.2

EX-99.2

Filename: exh_992.htm · Sequence: 8

EdgarFiling

EXHIBIT 99.2

Edesa Biotech Announces Pricing of $25.0 Million Public Offering

TORONTO, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA) (the “Company” or “Edesa”), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the pricing of an underwritten public offering consisting of (i) 3,870,500 common shares and accompanying common share warrants to purchase an aggregate of 3,870,500 common shares and (ii) in lieu of common shares to investors who so choose, pre-funded warrants to purchase up to 675,000 common shares and accompanying common share warrants to purchase an aggregate of 675,000 common shares, at an exercise price of $0.0001 per pre-funded warrant. Each common share and pre-funded warrant is being sold in combination with an accompanying common share warrant to purchase one common share. The common share warrants will have an exercise price of $7.50 per share, will be immediately exercisable from the date of issuance and will expire on the earlier of (x) the 18-month anniversary of the original issuance date and (y) 30 days following the Company’s public announcement of Phase 2 vitiligo topline data for EB06. The combined public offering price of each common share and accompanying common share warrant is $5.50. The combined public offering price of each pre-funded warrant and accompanying common share warrant is $5.4999, which represents the combined public offering price for the common shares and accompanying common share warrants less the $0.0001 per share exercise price for each pre-funded warrant. The gross proceeds are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, Edesa has granted the underwriters a 30-day option to purchase up to an additional 681,825 common shares and accompanying common share warrants to purchase up to 681,825 common shares at the public offering price, less underwriting discounts and commissions.

All common shares, pre-funded warrants and accompanying common share warrants are being offered by Edesa. The offering is expected to close on or about August 21, 2026, subject to the satisfaction of customary closing conditions.

Guggenheim Securities is acting as the sole book-running manager for the offering.

Edesa intends to use the net proceeds from the offering for general corporate purposes, which may include working capital, capital expenditures and research and development and manufacturing expenses.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-288966), including a base prospectus, that was declared effective by the Securities and Exchange Commission (“SEC”) on September 9, 2025. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and a final prospectus supplement with the final terms of the offering will be filed with the SEC and will be available for free on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, or by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

About Edesa Biotech, Inc.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by the use of words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “will,” “would,” “could,” “should,” “might,” “potential,” or “continue” and variations or similar expressions, including statements regarding the Company’s expectations regarding the satisfaction of customary closing conditions related to the offering, the expected closing of the offering and the anticipated use of proceeds therefrom. Readers should not unduly rely on these forward-looking statements, which are not a guarantee of future performance. There can be no assurance that forward-looking statements will prove to be accurate, as all such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the forward-looking statements. Such risks include: market and other conditions, those relating to the anticipated use of proceeds, the ability of Edesa to obtain regulatory approval for or successfully commercialize any of its product candidates, the risk that access to sufficient capital to fund Edesa’s operations may not be available or may be available on terms that are not commercially favorable to Edesa, the risk that Edesa’s product candidates may not be effective against the diseases tested in its clinical trials, the risk that Edesa fails to comply with the terms of license agreements with third parties and as a result loses the right to use key intellectual property in its business, Edesa’s ability to protect its intellectual property, the timing and success of submission, acceptance and approval of regulatory filings, and the impacts of public health crises. Many of these factors that will determine actual results are beyond the Company’s ability to control or predict. For a discussion of further risks and uncertainties related to Edesa’s business, please refer to Edesa’s reports filed with the U.S. Securities and Exchange Commission and the British Columbia Securities Commission. All forward-looking statements are made as of the date hereof and are subject to change. Except as required by law, Edesa assumes no obligation to update such statements.

Contact:

Gary Koppenjan

Edesa Biotech, Inc.

investors@edesabiotech.com

GRAPHIC

Filename: fasken.jpg · Sequence: 12

Binary file (1599 bytes)

Download fasken.jpg

GRAPHIC

Filename: exh51hdr.jpg · Sequence: 13

Binary file (8052 bytes)

Download exh51hdr.jpg

GRAPHIC

Filename: lslogo.jpg · Sequence: 14

Binary file (7748 bytes)

Download lslogo.jpg

GRAPHIC

Filename: lsfoot.jpg · Sequence: 15

Binary file (11461 bytes)

Download lsfoot.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 17

v3.26.1

Cover

Aug. 19, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 19, 2026

Entity File Number

001-37619

Entity Registrant Name

Edesa Biotech, Inc.

Entity Central Index Key

0001540159

Entity Incorporation, State or Country Code

Entity Address, Address Line One

100 Spy Court

Entity Address, City or Town

Markham

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

L3R 5H6

City Area Code

(289)

Local Phone Number

800-9600

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Shares

Trading Symbol

EDSA

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration